<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS206407</article-id><article-id pub-id-type="doi">10.1101/2025.06.06.658273</article-id><article-id pub-id-type="archive">PPR1034105</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A <italic>Slc5a6</italic> Deficient Mouse Model Reveals a Metabolically Driven Dilated Cardiomyopathy with Therapeutic Potential for Vitamin-Based Intervention</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fullerton</surname><given-names>Millie O.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Phillips</surname><given-names>Lauren C.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Redgrave</surname><given-names>Rachael E.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haufroid</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Merces</surname><given-names>George</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kerridge</surname><given-names>Scott T.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Richardson</surname><given-names>Gavin D.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mercier</surname><given-names>Nathalie</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Roland</surname><given-names>Dominique</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Dewulf</surname><given-names>Joseph P.</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A7">7</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Burn</surname><given-names>John</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Bamforth</surname><given-names>Simon D.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Phillips</surname><given-names>Helen M.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Biosciences Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kj2bm70</institution-id><institution>Newcastle University</institution></institution-wrap>, <city>Newcastle upon Tyne</city>, <country country="GB">United Kingdom</country></aff><aff id="A2"><label>2</label>Department of Pharmacology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap>, <country country="GB">United Kingdom</country></aff><aff id="A3"><label>3</label>Louvain Center for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique (IREC), <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02495e989</institution-id><institution>UCLouvain</institution></institution-wrap>, <city>Brussels</city>, <country country="BE">Belgium</country></aff><aff id="A4"><label>4</label>Image Analysis Unit, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kj2bm70</institution-id><institution>Newcastle University</institution></institution-wrap>, <city>Newcastle upon Tyne</city>, <country country="GB">United Kingdom</country></aff><aff id="A5"><label>5</label>Department of Pediatrics, CHU HELORA Jo, La Louvière, Belgium</aff><aff id="A6"><label>6</label>Department of Human Genetics, Center for Inherited Metabolic Disorders, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00zam0e96</institution-id><institution>Institute of Pathology and Genetics</institution></institution-wrap>, <city>Gosselies</city>, <country country="BE">Belgium</country></aff><aff id="A7"><label>7</label>Metabolic Research Group, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/022em3k58</institution-id><institution>de Duve Institute</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02495e989</institution-id><institution>UCLouvain</institution></institution-wrap>, <city>Brussels</city>, <country country="BE">Belgium</country></aff><aff id="A8"><label>8</label>Biochemical Genetics and Newborn Screening Laboratory, Department of laboratory medicine &amp; Institut des Maladies Rares, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03s4khd80</institution-id><institution>Cliniques Universitaires Saint-Luc</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02495e989</institution-id><institution>UCLouvain</institution></institution-wrap>, <city>Brussels</city>, <country country="BE">Belgium</country></aff><aff id="A9"><label>9</label>Translational and Clinical Research Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kj2bm70</institution-id><institution>Newcastle University</institution></institution-wrap>, <city>Newcastle upon Tyne</city>, <country country="GB">United Kingdom</country></aff><author-notes><corresp id="CR1">
<label>*</label>Corresponding author, Helen M. Phillips. Mailing address: Biosciences Institute, Faculty of Medical Sciences, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ. <email>Helen.Phillips@newcastle.ac.uk</email></corresp><fn id="FN1"><p id="P1">Work was performed at Newcastle University and Brussels Belgium, B-1200, Alma Campus.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>14</day><month>06</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>09</day><month>06</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Background and Aims</title><p id="P2">The sodium-dependent multivitamin transporter, encoded by <italic>SLC5A6</italic>, mediates cellular uptake of the vitamins, biotin and pantothenic acid, both of which are essential cofactors for energy metabolism. Here, we report two families with <italic>SLC5A6</italic> mutations presenting with early-onset dilated cardiomyopathy (DCM). To investigate the link between vitamin deficiency and DCM, we generated a novel cardiac-specific <italic>Slc5a6</italic> knockout (<italic>Slc5a6</italic><sup><italic>cKO</italic></sup>) mouse model and tested the therapeutic potential of vitamin supplementation.</p></sec><sec id="S2"><title>Methods</title><p id="P3">Cardiac function in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice was assessed by cardiac magnetic resonance imaging and ECG measurements. Histological, biochemical, and proteomic analyses were conducted to identify structural and metabolic changes. The impact of dietary biotin and pantothenic acid supplementation on disease progression was evaluated.</p></sec><sec id="S3"><title>Results</title><p id="P4"><italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice developed progressive cardiac dysfunction, manifesting as DCM with cardiac dilation, cardiomyocyte hypertrophy, fibrosis, impaired Coenzyme A synthesis, and metabolic imbalance, culminating in premature death by 26 weeks. Proteomic analysis revealed early mitochondrial metabolic disruption and extracellular matrix protein upregulation at 8 weeks, preceding overt cardiac dysfunction. Strikingly, vitamin supplementation from preconception onwards, prevented the cardiac phenotype, preserving cardiac structure, function, morphology and survival. This parallels the clinical outcome in one patient who received early vitamin treatment, compared to another who required a heart transplant following delayed vitamin treatment.</p></sec><sec id="S4"><title>Conclusions</title><p id="P5">This study establishes a direct link between SLC5A6-mediated vitamin transport, mitochondrial function, and cardiac health. It highlights how vitamin deficiency contributes to DCM pathogenesis and supports early vitamin supplementation as a potential therapeutic strategy for metabolic cardiomyopathies.</p></sec></abstract><abstract abstract-type="graphical"><p id="P6"><fig id="F8" position="anchor"><graphic xlink:href="EMS206407-f008"/></fig>
</p></abstract><kwd-group><kwd>Cardiomyopathy</kwd><kwd>vitamins</kwd><kwd>mitochondria</kwd><kwd>energy metabolism</kwd><kwd><italic>SLC5A6</italic></kwd><kwd>SMVT</kwd></kwd-group></article-meta></front><body><sec id="S5" sec-type="intro"><title>Introduction</title><p id="P7">Dilated cardiomyopathy (DCM) is a leading cause of cardiovascular morbidity and mortality, affecting approximately 1 in 250 people in the UK, characterised by enlargement and dilation of one or more ventricles with impaired contractility, reduced left ventricular ejection fraction (EF) and heart failure. Paediatric cases of DCM are particularly severe, with over one-third of affected children requiring heart transplantation.<sup>(<xref ref-type="bibr" rid="R1">1</xref>)</sup> The aetiology of DCM includes both genetic and environmental factors, such as mutations in sarcomeric genes<sup>(<xref ref-type="bibr" rid="R2">2</xref>)</sup> or exposure to cardiotoxic drugs.<sup>(<xref ref-type="bibr" rid="R3">3</xref>)</sup> Many cases of DCM, however, are idiopathic, and the complex pathological mechanisms underlying DCM are still not well understood. The heart is the most metabolically demanding organ in the body, requiring high ATP turnover, given the critical role of mitochondria in energy metabolism, disruptions in mitochondrial dynamics and function have been strongly linked to cardiovascular disease and heart failure.<sup>(<xref ref-type="bibr" rid="R4">4</xref>)</sup></p><p id="P8"><italic>SLC5A6</italic> encodes the highly conserved and ubiquitously expressed sodium-dependent multivitamin transporter (SMVT), a member of the amino acid-polyamine organocation superfamily, sodium/solute symporters, which allow the unilateral transport of molecules across the cell membrane.<sup>(<xref ref-type="bibr" rid="R5">5</xref>–<xref ref-type="bibr" rid="R7">7</xref>)</sup> It is required for the uptake of water-soluble vitamins biotin (vitamin B7), pantothenic acid (vitamin B5) and lipoic acid.<sup>(<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R9">9</xref>)</sup> Biotin and pantothenic acid are acquired from the diet <sup>(<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R10">10</xref>)</sup> and are vital for energy production via the tricarboxylic acid (TCA) cycle, amino acid catabolism and fatty acid synthesis.</p><p id="P9">Patients with homozygous or compound heterozygous mutations in <italic>SLC5A6</italic> encompass an autosomal recessive disorder and exhibit a wide spectrum of multisystemic clinical manifestations, including developmental and growth delay, neurodegenerative disorders, gastrointestinal problems, immunodeficiency, seizures and osteopenia.<sup>(<xref ref-type="bibr" rid="R11">11</xref>–<xref ref-type="bibr" rid="R23">23</xref>)</sup> However, the influence of <italic>SLC5A6</italic> mutations on cardiovascular health and function has not been studied.</p><p id="P10">Here, we describe three patients, two of whom are from a newly identified consanguineous family and compare it with a previously published patient<sup>(<xref ref-type="bibr" rid="R18">18</xref>)</sup>, both of which presented with early onset DCM and homozygous <italic>SLC5A6</italic> mutations. Family 1 has two affected siblings, one of whom died prematurely, while the other had a life-saving heart transplant, prior to receiving vitamin supplementation at a later stage. In the second family, the patient similarly presented with severe heart failure but had a successful response to early vitamin supplementation, thus preventing the need for a transplant.</p><p id="P11">To investigate an association between DCM and vitamin deficiency, we generated a novel cardiac-specific conditional deletion of <italic>Slc5a6</italic> in mice (<italic>Slc5a6</italic><sup><italic>cKO</italic></sup>). These mice exhibited a progressive DCM-like phenotype, culminating in premature death around 26 weeks. We identified abnormalities in cardiac function and protein expression preceding the onset of histological manifestations. Metabolomic and proteomic analyses of <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts revealed disruptions in metabolic pathways and an increase in fibrosis-associated proteins from as early as 8 weeks of age. Remarkably, vitamin supplementation completely ameliorated the DCM phenotype, with functional, pathological and protein expression changes completely absent.</p></sec><sec id="S6" sec-type="methods"><title>Methods</title><p id="P12">Detailed methods are provided in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Material</xref>.</p></sec><sec id="S7" sec-type="results"><title>Results</title><sec id="S8"><title>Clinical manifestations and progression of DCM in two consanguineous families</title><p id="P13">In Family 1, which is of Pakistani ethnicity, three siblings were born to healthy consanguineous parents (<xref ref-type="fig" rid="F1">Figure 1A</xref>). All pregnancies carried to full term without any complications. Sibling II-1 died at 24 months due to DCM. Patient II-2 developed an acute illness at 9 months, characterized by hypoglycaemia and lethargy, which rapidly progressed to respiratory failure, necessitating paediatric intensive care unit admission and mechanical ventilation for two weeks. During this time, total parenteral nutrition (TPN) was given, and clinical indicators of DCM were first identified. A subsequent admission occurred at 21 months due to cardiac dysfunction requiring inotropic support, and the patient developed pneumonia, left-sided paralysis, and seizures. Mild developmental delay was noted, and nutritional support was administered via nasogastric tube due to feeding difficulties. The patient then remained well for two years. However, at 4 years of age, the patient relapsed and experienced cardiac decompensation and had poor cardiac output, with imaging revealing a dilated, enlarged heart and evidence of cardiac failure (<xref ref-type="supplementary-material" rid="SD1">Figure S1A</xref>). A left ventricular assist device (LVAD) was inserted for seven weeks, facilitating cardiac recovery and the patient was given vitamin supplementation of riboflavin, thiamine, ascorbic acid, and ubiquinone during this time. At 5 years old, another acute cardiac event triggered readmission with a second LVAD inserted for two weeks and TPN was administered. Cardiac function recovered and was stable for two years. At this point, the patient presented with lethargy and cardiorespiratory insufficiency and a third LVAD was inserted until a donor heart was transplanted a week later, age 7. Clinical follow-up showed no rejection and good cardiac function and the stability of the transplant is maintained on tacrolimus 1mg daily and mycophenolate mofetil 500mg twice daily. Additional clinical complications included developmental delay, persistent left hemiplegia, complete areflexia, and recurrent seizures. Metabolic screening at 7 years demonstrated increased excretion of 3-hydroxyisovaleric acid (3HIA) in urine, and increased 3-hydroxyisovaleryl-carnitine (C5OH) in both urine and a blood spot, consistent with 3-methylcrotonyl-CoA carboxylase and biotinidase deficiency.<sup>(<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R25">25</xref>)</sup> At 14 years, based on the molecular findings (described below), supplementation was commenced with daily doses of pantothenic acid (550mg), lipoic acid (400mg) and biotin (10mg). Subsequently daily ferrous sulphate (210mg) was added in 2023 after diagnosis of iron deficiency associated with recurrent episodes of loose stools and hair loss. Epilepsy is controlled with twice daily zonesamide (200mg), lamotrigine (225mg), clonazepam (10mg) and brivaracetam (50mg). Infection is suppressed with co-trimoxazole 480mg daily. Assessing the impact of the vitamin supplements has been challenging in an adolescent with multiple medical problems. The parents are excellent observers and consider growth, development and epilepsy control have all improved after six years on supplements. Puberty commenced normally. She continues to have occasional seizures at the time of her periods.</p><p id="P14">A myocardial biopsy obtained during LVAD insertion showed myocardial disarray, featuring hypertrophied cardiomyocytes (<xref ref-type="fig" rid="F1">Figure 1B</xref>) with large, irregular, hyperchromatic nuclei. There was also evidence of mild interstitial, perimyocyte and subendocardial fibrosis (<xref ref-type="fig" rid="F1">Figure 1C</xref>). Transmission electron microscopy (TEM) images of the left ventricle revealed sarcomeric wasting and disarray. In some areas, the sarcomeres had fragmented, creating white patches, and the organised parallel alignment of the sarcomeres was lost. Z band disarray was evident, indicated by variations in the thickness of the lines. Additionally, large clusters of mitochondria were observed, containing some fragmented mitochondria (<xref ref-type="fig" rid="F1">Figure 1D-G</xref>). The examining pathologist diagnosed cardiomyopathy with no morphological evidence as to the cause.</p><p id="P15">In Family 2,<sup>(<xref ref-type="bibr" rid="R18">18</xref>)</sup> consanguineous parents from Tunisia, had five children (<xref ref-type="supplementary-material" rid="SD1">Figure S1B</xref>). Child II-2 died of unexplained multisystemic decompensation and severe cardiac dysfunction at 8 months (genetic testing was not available at that time) and patient II-5 presented with severe cardiac decompensation at 5 months, with a left ventricular EF of 32% (normal &gt;60%; classed as Day 0 on <xref ref-type="supplementary-material" rid="SD1">Figure S1C</xref>). Treatment with cardiac drugs (adrenaline, milrinone and furosemide) for 3 days resulted in EF improvement to 62% by Day 10. However, by Day 22, the patient had relapsed with an EF of 17%, necessitating intensive cardiac support with an increasing number of cardiac drugs (digoxin, furosemide, spironolactone, carvedilol and lisinopril). Additionally, following an abnormal plasma acylcarnitine’s profile and a persistent increase in 3-hydroxyisovaleric acid in the urine (3-HIA), biotin supplementation (10 mg on Day 22, increased to 15 mg on Day 33) and then pantothenic acid (100 mg from Day 64) were initiated. Following the increase in biotin dose to 15mg, the EF increased to 45% and the patient was maintained on vitamins and four cardiac drugs (digoxin, furosemide, carvedilol and lisinopril) for a further 79 days. The number of cardiac drugs were slowly reduced as the EF rose to a healthy 66% on Day 121 and 75% on Day 150 (<xref ref-type="supplementary-material" rid="SD1">Figure S1B</xref>). Bi-vitamin supplementation remains ongoing, and the EF has remained within the normal range. The patient also presented with severe hypogammaglobulinemia that interestingly corrected itself after vitamin supplementation.</p></sec><sec id="S9"><title>Identification of <italic>SLC5A6</italic> mutation and protein modelling</title><p id="P16">Whole-exome sequencing of Family 1 revealed a novel homozygous missense variant in <italic>SLC5A6</italic> ((GRCh37) Chr2:27427777 G&gt;A) in patients II-1 and II-2. The mutation results in a substitution of arginine at position 253 to a tryptophan (p.R253W). All unaffected family members were heterozygous for the variant (<xref ref-type="fig" rid="F1">Figure 1A</xref>).</p><p id="P17">The mutation, in exon 9, affects a highly conserved amino acid (<xref ref-type="fig" rid="F1">Figure 1H</xref>), with an allele frequency of 0.00001983 (gnomADv4.1) and a high pathogenicity prediction (CADD score: 27.4). Within the SMVT transporter the R253W mutation is located on the extracellular loop between transmembrane domains 6 and 7, spanning the hinge region of the LeuT fold (<xref ref-type="fig" rid="F1">Figure 1I</xref>). <italic>In silico</italic> protein modelling indicated that the substitution of arginine to tryptophan introduces a large bulky aromatic ring, which is predicted to induce steric hindrance (<xref ref-type="fig" rid="F1">Figure 1J-L</xref>) and prevent the formation of a salt bridge with E91 (<xref ref-type="fig" rid="F1">Figure 1M,N</xref>).</p><p id="P18">Protein modelling of the P437L mutation (C&gt;T) in <italic>SLC5A6</italic>, again in a highly conserved residue, (<xref ref-type="supplementary-material" rid="SD1">Figure S1D,E</xref>) reported in Family 2,<sup>(<xref ref-type="bibr" rid="R18">18</xref>)</sup> showed the overall positioning of the large intracellular loop changes and a novel polar bond is formed between L437 and V434 (<xref ref-type="supplementary-material" rid="SD1">Figure S1F-J</xref>).</p><p id="P19">Both pathogenic mutations in <italic>SLC5A6</italic>, therefore, predicted to induce conformational changes in the tertiary structure of the protein, and the likely outcome of these mutations is affected vitamin uptake.</p></sec><sec id="S10"><title><italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice develop cardiomyopathy</title><p id="P20">Mice constitutively deficient for <italic>Slc5a</italic>6 (<xref ref-type="supplementary-material" rid="SD1">Figure S2A</xref>) exhibited embryonic lethality, with underdeveloped embryos at embryonic day (E)9.5 and E10.5 (<xref ref-type="supplementary-material" rid="SD1">Figure S2B-E</xref>). The number of <italic>Slc5a6</italic><sup><italic>Tm1a/Tm1a</italic></sup> mutant embryos was significantly underrepresented when collected between E9.5 and E15.5 (<xref ref-type="supplementary-material" rid="SD1">Figure S2F</xref>).</p><p id="P21">SLC5A6 was confirmed to be strongly expressed in the mouse and human embryonic heart (<xref ref-type="supplementary-material" rid="SD1">Figure S2H-K</xref>). A cardiac-specific <italic>Slc5a6</italic> knockout (KO) (<italic>Slc5a6</italic><sup><italic>cKO</italic></sup>) mouse line was produced by crossing conditional <italic>Slc5a6</italic><sup><italic>Tm1c</italic></sup> mice with the <italic>Tnt-Cre</italic> line (<xref ref-type="supplementary-material" rid="SD1">Figure S2A</xref>). RT-PCR confirmed heart-specific deletion of exons 7-10 (<xref ref-type="supplementary-material" rid="SD1">Figure S2L</xref>) resulting in a premature stop codon (<xref ref-type="supplementary-material" rid="SD1">Figure S2A</xref>). The <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice were observed at the expected numbers at weaning (<xref ref-type="supplementary-material" rid="SD1">Figure S2M</xref>).</p><p id="P22">Histological analysis at E15.5 revealed that <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> embryos displayed no developmental cardiac abnormalities (<xref ref-type="fig" rid="F2">Figure 2A,B</xref>). <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice were phenotypically normal at birth and into early adulthood, but by 20 weeks there was a significant decrease in body weight (<italic>p</italic>=0.0195; <xref ref-type="supplementary-material" rid="SD1">Figure S2N</xref>). Sudden death occurred in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice at 26 weeks (<italic>n</italic>=3), prompting euthanasia of subsequent litters by 20 weeks. Histological analysis of the hearts revealed severe cardiac dilation, with enlarged atria and ventricles (<xref ref-type="fig" rid="F2">Figure 2C-F</xref>). At 14 weeks cardiomyocyte hypertrophy was observed in both the right and left ventricles (LV <italic>p</italic>=0.0016, RV <italic>p</italic>=0.0067; <xref ref-type="fig" rid="F2">Figure 2G-I</xref>). No differences were observed in heart weight to body weight or to tibia length ratios (<xref ref-type="fig" rid="F2">Figures 2J</xref>; <xref ref-type="supplementary-material" rid="SD1">S2O</xref>), suggesting the heart is dilated with a larger internal volume but no increase in mass. Fibrosis was significantly increased 3-fold throughout the ventricular walls of the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts compared to control hearts (<italic>p</italic>=0.0007; <xref ref-type="fig" rid="F2">Figure 2K-M</xref>). An increase in atrial natriuretic peptide (<italic>Nppa</italic>; <italic>p</italic>=0.037) and a decrease in alpha-cardiac myosin heavy chain (<italic>Myh6</italic>; <italic>p</italic>=0.0432) expression were observed in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts at 20 weeks (<xref ref-type="supplementary-material" rid="SD1">Figure S2P,Q</xref>).</p><p id="P23">Thus, the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice develop the key features of DCM with a dilated heart, cardiomyocyte hypertrophy, fibrosis and fetal gene reprogramming.</p></sec><sec id="S11"><title>Cardiac function is severely reduced in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice</title><p id="P24">Cardiovascular Magnetic Resonance (CMR) imaging and three-lead ECG readings were used to assess the impact of cardiac structural abnormalities on cardiac function. CMR performed at 20 weeks demonstrated significantly impaired cardiac function in the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants (<italic>n</italic>=4), with significant decreases in EF (<italic>p</italic>=0.0207; 28.8% ±12.29 compared to 61% ±19.72 in controls (<italic>n</italic>=6)), stroke volume (SV, <italic>p</italic>=0.0146; 16.1µl ±6.74 compared to 34.4µl ±10.3 in controls), and cardiac output (CO, <italic>p</italic>=0.007; 6.8ml/min ±2.1 compared to 15.8ml/min ±4.63 in controls) (<xref ref-type="fig" rid="F3">Figure 3A-C</xref>).</p><p id="P25">ECG was performed from 8 to 20 weeks on control and <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice to monitor cardiac function in vivo. However, due to the natural variation between mouse heart rhythms and progression of disease with time, not all parameters could be accurately quantified at each time point from the average ECG traces. For example, at 20 weeks there was a clear visual difference between the ECG traces from control and <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice, with the flattened <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> trace with no clearly defined ST wave (<xref ref-type="fig" rid="F3">Figure 3G,I</xref>). Data was, therefore, tabulated to show the percentage of mice for which each parameter could be calculated (<xref ref-type="table" rid="T1">Table 1</xref>). This demonstrated an overall defect in cardiac conduction from 8 weeks which deteriorated severely by 20 weeks, which was further emphasized as ECG traces were only quantifiable in 7.1% of <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice compared to 100% of controls.</p><p id="P26">Analysis of the quantifiable ECG parameters at 8 weeks showed a significant increase in PR interval (<italic>p</italic>=0.004; <xref ref-type="fig" rid="F3">Figure 3K</xref>, control <italic>n</italic>=12, <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> <italic>n</italic>=10) and a decrease in T amplitude (<italic>p</italic>=0.0483; <xref ref-type="supplementary-material" rid="SD1">Figure S3B</xref>, control <italic>n</italic>=13, <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> <italic>n</italic>=7) in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice. Heart rate was consistently lower in the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice (<italic>p</italic>=0.0004; <xref ref-type="fig" rid="F3">Figure 3M</xref>, control <italic>n</italic>=13, <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> <italic>n</italic>=17).</p><p id="P27">The cardiac-specific deletion of <italic>Slc5a6</italic>, therefore, caused anatomical, histological and functional cardiac alterations typical of DCM, resulting in sudden death by 26 weeks. Thus, the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mouse is a good model of DCM, recapitulating the DCM seen in the patients.</p></sec><sec id="S12"><title><italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice have reduced vitamin transport</title><p id="P28">To establish the cause of DCM, mass spectrometry metabolomic analyses of 8-week <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice was performed and compared with control mice. Biotin, a cofactor for carboxylases, and pantothenic acid, required for the synthesis of CoA, are both transported by SMVT.<sup>(<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R27">27</xref>)</sup> FIA-MS/MS analysis of plasma acylcarnitine revealed a significant increase in 3-hydroxyisovaleryl-carnitine (C5OH) (<italic>p</italic>=0.0002; <xref ref-type="fig" rid="F4">Figure 4A</xref>), a hallmark of 3-methylcrotonyl-CoA carboxylase (MCC) and biotinidase deficiency. LC-MS-qTOF analysis on heart powder detected significantly increased levels of 3-hydroxyisovaleric acid (3-HIA; <italic>p</italic>&lt;0.0001) and 2-methylcitric acid (2MCA; <italic>p</italic>=0.0017), indicative of MCC and propionyl-CoA carboxylase (PCC) deficiencies, respectively (<xref ref-type="fig" rid="F4">Figure 4B,C</xref>). Additionally, cardiac levels of pantothenic acid (<italic>p</italic>&lt;0.0001), and its derivatives phosphopantothenic acid (<italic>p</italic>&lt;0.0001) and phosphopantethein (<italic>p</italic>=0.0219) were significantly decreased, leading to impaired CoA synthesis, as evidenced by reduced CoA-glutathione (<italic>p</italic>=0.0002) (<xref ref-type="fig" rid="F4">Figure 4D-G</xref>). Western blot analysis confirmed a significant reduction in MCC and PCC biotinylation in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts at 5 weeks (before any structural or functional cardiac differences were observed; <italic>p</italic>=0.0178) and 20 weeks (experimental endpoint; <italic>p</italic>=0.0006) (<xref ref-type="fig" rid="F4">Figures 4H,J</xref>; <xref ref-type="supplementary-material" rid="SD1">S4A,C</xref>), which was unchanged in the liver (<xref ref-type="fig" rid="F4">Figures 4I,K</xref>; <xref ref-type="supplementary-material" rid="SD1">S4B,D</xref>). Pyruvate carboxylase (PC) levels were unaffected (<xref ref-type="fig" rid="F4">Figures 4M-P</xref>; <xref ref-type="supplementary-material" rid="SD1">S4A-D</xref>). Thus, these results indicated biochemically there was a heart-specific reduction in biotin and pantothenic acid transport in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice.</p></sec><sec id="S13"><title>Vitamin supplementation ameliorates the DCM phenotype</title><p id="P29">As patient II-5 in Family 2 responded well to early vitamin treatment, to specifically assess the impact of vitamin supplementation on heart function, biotin and pantothenic acid were added to the water and diet of <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice at doses equivalent to those used in humans (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>).<sup>(<xref ref-type="bibr" rid="R28">28</xref>)</sup> Supplementation was initiated in parental mice before conception, continued throughout gestation and provided long-term to the offspring. Maintenance of normal levels of MCC and PCC biotinylation in 20-week hearts of supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice (<xref ref-type="fig" rid="F4">Figure 4L</xref>) indicated successful vitamin uptake.</p><p id="P30">Vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice survived to 40 weeks, at which time the mice were electively culled. Vitamin supplementation did not affect body weight at 20 or 40 weeks (<xref ref-type="supplementary-material" rid="SD1">Figure S5A-F</xref>) and it prevented the excessive deposition of fibrosis in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts (<xref ref-type="fig" rid="F2">Figures 2N-P</xref>; <xref ref-type="supplementary-material" rid="SD1">S5G-K</xref>) and there was no longer altered expression of <italic>Nppa</italic> and <italic>Myh6</italic> at 20 weeks (<xref ref-type="supplementary-material" rid="SD1">Figure S2R,S</xref>). There were no discernible differences in cardiac function; EF, SV or CO between vitamin-supplemented control and <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice (<xref ref-type="fig" rid="F3">Figure 3D-F</xref>), and all ECG traces could be quantified at 20 weeks (<xref ref-type="fig" rid="F3">Figure 3H,J</xref>; <xref ref-type="table" rid="T1">Table 1</xref>). No significant difference in any ECG parameter was observed at any time point (<xref ref-type="fig" rid="F3">Figures 3K-N</xref>; <xref ref-type="supplementary-material" rid="SD1">S3A-E</xref>). Vitamin supplementation, therefore, prevented all the hallmarks of DCM observed in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice.</p></sec><sec id="S14"><title>Mitochondrial complexity increases with disease progression in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice</title><p id="P31">As changes in mitochondria morphology are associated with metabolic dysfunction and disease progression,<sup>(<xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R30">30</xref>)</sup> we analysed the ultrastructure of cardiac mitochondria using TEM.</p><p id="P32">At 20 weeks, control hearts presented with predominantly spherical shaped mitochondria, with minimal branching or complex shapes, and formed parallel clusters along longitudinal myofibers (<xref ref-type="fig" rid="F5">Figures 5A,C</xref>; <xref ref-type="supplementary-material" rid="SD1">S7A-D</xref>). In contrast, mitochondria in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts were irregularly shaped and arranged randomly between myofibrils with evidence of mitochondrial degradation (<xref ref-type="fig" rid="F5">Figures 5B,D</xref>; <xref ref-type="supplementary-material" rid="SD1">S7E-L</xref>). The mitochondrial complexity index (MCI) was significantly increased in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts (<italic>p</italic>&lt;0.0001) with a corresponding significant decrease in volume (<italic>p</italic>&lt;0.0001; <xref ref-type="fig" rid="F5">Figure 5I,J</xref>; <xref ref-type="table" rid="T2">Table 2</xref>). The <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts, therefore, had smaller mitochondria, with more complex shapes including excessive elongation, branching and nanotunnels (<xref ref-type="supplementary-material" rid="SD1">Figure S7M-P</xref>). This is further represented by the significant difference in the lines of best fit for controls versus <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts on the bivariate plot (<italic>p</italic>&lt;0.0001; <xref ref-type="fig" rid="F5">Figure 5K</xref>) and a shift to the right in the cumulative frequency distributions (<xref ref-type="fig" rid="F5">Figure 5L</xref>).</p><p id="P33">To establish if the changes in mitochondria morphology were associated with early indicators of disease, the mitochondria were investigated at 8 weeks. The overall arrangement of the parallel clusters of the mitochondria along the myofibrils was similar between control and <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice (<xref ref-type="supplementary-material" rid="SD1">Figure S6A,B</xref>). There was, however, a significant increase in the MCI of mitochondria in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts compared to controls (<italic>p</italic>=0.0075), although there was no change in volume (<xref ref-type="supplementary-material" rid="SD1">Figure S6C,D,I-L</xref>; <xref ref-type="table" rid="T2">Table 2</xref>).</p><p id="P34">Cardiac mitochondria morphology was then assessed in vitamin-supplemented mice. At 20 weeks the morphology of mitochondria was similar between control and <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts, and there was a significant reduction in MCI (<italic>p</italic>=0.0013) but no change in volume (<xref ref-type="fig" rid="F5">Figures 5E-H,M,N</xref>; <xref ref-type="table" rid="T2">Table 2</xref>), suggesting that vitamins prevented the abnormal mitochondrial morphology. The bivariate plot of mitochondrial MCI:volume and cumulative MCI frequency showed no differences between vitamin-supplemented control and <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts at 20 weeks (<xref ref-type="fig" rid="F5">Figure 5O,P</xref>). At 8 weeks there was a small yet significant decrease in MCI (<italic>p</italic>=0.0462) but not volume (<xref ref-type="supplementary-material" rid="SD1">Figure S6E-H,M,N</xref>; <xref ref-type="table" rid="T2">Table 2</xref>). Interestingly, in vitamin-supplemented mice at 8 weeks, the correlation between the spread of the mitochondria was similar but still significantly different (<italic>p</italic>=0.0084; <xref ref-type="supplementary-material" rid="SD1">Figure S6O,P</xref>).</p><p id="P35">The subtle change in mitochondria complexity at 8 weeks coincides with the early indication of cardiac dysfunction in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice. As DCM progresses towards heart failure at 20 weeks, the mitochondria become more complex in shape and is associated with a corresponding increase in mitochondria degradation. Vitamin-supplementation mitigates this effect in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice.</p></sec><sec id="S15"><title>Altered metabolism pathways underlie the onset of DCM in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice</title><p id="P36">To elucidate the cellular mechanism driving DCM progression in the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice, we performed an unbiased proteomics analysis to identify altered signalling pathways at 8 weeks before the overt DCM phenotype was evident. Protein was extracted from control and <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts, from normal diet and vitamin-supplemented animals (<italic>n</italic>=5 per group).</p><p id="P37">Analysis of differential protein expression, using principal component analysis and a hierarchical heat map plot, showed that the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> samples formed a distinct group compared to the control and vitamin-supplemented samples (<xref ref-type="fig" rid="F6">Figure 6A,B</xref>).</p><p id="P38">For normal diet, a total of 1459 proteins showed significant differential expression (599 downregulated, 860 upregulated; <italic>p</italic>&lt;0.05) in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts compared to controls (<xref ref-type="fig" rid="F6">Figure 6C</xref>). For the vitamin-supplemented mice, only 153 proteins showed significant differential expression (81 downregulated, 72 upregulated; <italic>p</italic>&lt;0.05) in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts compared to controls (<xref ref-type="fig" rid="F6">Figure 6D</xref>). Of the proteins differentially expressed under a normal diet, only 124 of those proteins remained significantly differentially expressed following vitamin supplementation (<xref ref-type="fig" rid="F6">Figure 6E</xref>). There was no significant difference in protein expression between the normal diet and vitamin-supplemented control samples.</p><p id="P39">Pathway analysis was performed on the significantly down- and up-regulated proteins combined. From mice on a normal diet, in the top 15 significantly enriched pathways (<xref ref-type="fig" rid="F6">Figure 6F</xref>), the upregulated pathways included the ‘sirtuin signalling pathway’ and ‘collagen biosynthesis and modifying enzymes’, which are both linked to increasing fibrosis,<sup>(<xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R32">32</xref>)</sup> and ‘Granzyme A signalling’ which correlates with the upregulation of mitochondrial dysfunction pathways.<sup>(<xref ref-type="bibr" rid="R33">33</xref>)</sup> There was downregulation of key pathways in energy metabolism: ‘respiratory electron transport’, ‘mitochondrial translation’, ‘oxidation phosphorylation’, ‘complex I biogenesis’, ‘branched-chain amino acid catabolism (BCAA)’ (specifically valine and isoleucine degradation), and ‘fatty acid beta-oxidation’. Hematome resolution signalling pathway is linked to genes involved in peroxisomal beta-oxidation.<sup>(<xref ref-type="bibr" rid="R34">34</xref>)</sup> In contrast, the dramatically reduced number of enriched pathways in the vitamin-supplemented hearts (<xref ref-type="fig" rid="F6">Figure 6G</xref>), highlighted there was only downregulation of peroxisome related pathways.</p><p id="P40">Correlation analyses illustrated that key metabolic pathways were affected following vitamin supplementation. Proteins associated with the fatty acid β-oxidation pathway, which were downregulated, clustered below the line of best fit in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts, then aligned with control levels in vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts (<xref ref-type="fig" rid="F6">Figures 6H-J</xref>). Similarly, collagen biosynthesis proteins, which were upregulated in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts, aligned with control levels after supplementation (<xref ref-type="fig" rid="F6">Figures 6K-M</xref>).</p><p id="P41">Energy metabolism involves several interconnected pathways. Analysis of different pathways showed that the majority of proteins linked to the TCA cycle, fatty acid metabolism, BCAA catabolism and the electron transport chain were all downregulated in the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts on a normal diet, with a corresponding increase in proteins involved in glycolysis (<xref ref-type="fig" rid="F7">Figure 7A</xref>), which is a common compensatory response in heart failure.<sup>(<xref ref-type="bibr" rid="R35">35</xref>)</sup></p><p id="P42">Each mitochondrial complex (C) in the electron transport chain, CI to CV, is made from multiple subunits. Notably, from the subunits detected in the proteomics experiment, the components exhibited widespread reduced expression in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants compared to controls, with the following percentage of subunits showing decreased expression: CI 90.2%, CII 100%, CIII 77.8%, CIV 77%, CV 76.5% (q&lt;0.05, all FC; <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>). Remarkably, vitamin supplementation substantially prevented these deficits, reducing the proportion of downregulated subunits to only two in CI (NDUFA11 and NDUFS6) and one in CIV (MT-CO3) in vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts compared to controls. These findings were further validated by qPCR analysis of representative subunits of each complex highlighted in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>, which confirmed significant downregulation in Complexes I (<italic>p</italic>=0.0079), II (<italic>p</italic>=0.0142), IV (<italic>p</italic>&lt;0.0001), and V (<italic>p</italic>=0.0141) in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts (<xref ref-type="fig" rid="F7">Figure 7B-F</xref>), with no significant differences detected in vitamin-treated hearts (<xref ref-type="fig" rid="F7">Figure 7G-K</xref>).</p><p id="P43">Overall, these findings demonstrate that <italic>Slc5a6</italic> deficiency disrupts the cardiac proteome homeostasis, leading to metabolic defects and extracellular matrix remodelling. Importantly, vitamin supplementation effectively mitigates these molecular perturbations, maintaining proteomic profiles at control levels and preventing DCM progression.</p></sec></sec><sec id="S16" sec-type="discussion"><title>Discussion</title><p id="P44">In this study, we identified <italic>SLC5A6</italic> mutations as a novel genetic cause of dilated cardiomyopathy (DCM) in two unrelated families. Clinical outcomes in these families highlight the critical importance of early intervention: timely and sustained vitamin supplementation prevented the progression to end-stage heart failure and the need for heart transplantation, whereas delayed treatment was associated with irreversible cardiac decline requiring transplantation. Using a cardiac deletion mouse model of <italic>Slc5a6, Slc5a6</italic><sup><italic>cKO</italic></sup>, we confirmed that <italic>Slc5a6</italic> is a novel DCM causative gene linked to abnormal mitochondria and impaired energy metabolism which are prevented with vitamin supplementation.</p><p id="P45">The clinical symptoms in patients with <italic>SLC5A6</italic> mutations typically manifest between one week to 15 years, with 18% of patients dying with no reported treatment. It is an autosomal recessive disease, but with no obvious genotype:phenotype correlation. A third of patients exhibit cardiac complications including ventricular fibrillation,<sup>(<xref ref-type="bibr" rid="R13">13</xref>)</sup> left ventricle dysfunction,<sup>(<xref ref-type="bibr" rid="R18">18</xref>)</sup> non-specific ST and T wave abnormalities<sup>(<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R22">22</xref>)</sup> and DCM, requiring heart transplantation.<sup>(<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R17">17</xref>)</sup></p><p id="P46">In <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice, inactivation of <italic>Slc5a6</italic> specifically in cardiomyocytes results in a lethal phenotype with characteristic anatomical, functional and histological features consistent with DCM.<sup>(<xref ref-type="bibr" rid="R36">36</xref>–<xref ref-type="bibr" rid="R38">38</xref>)</sup> The <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice were phenotypically normal up to 8 weeks when abnormal ECG readings were identified, demonstrating early indicators of DCM.<sup>(<xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R40">40</xref>)</sup> The <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice had a lower heart rate, consistent with the known inverse correlation between heart rate and PR interval.<sup>(<xref ref-type="bibr" rid="R41">41</xref>)</sup> CMR imaging revealed that mutant mice had an EF of ~28.8% at 20 weeks. Patients presenting with an EF of less than 40% are diagnosed with heart failure. <sup>(<xref ref-type="bibr" rid="R42">42</xref>, <xref ref-type="bibr" rid="R43">43</xref>)</sup> This correlated well with reactivation of the fetal gene programme<sup>(<xref ref-type="bibr" rid="R44">44</xref>–<xref ref-type="bibr" rid="R46">46</xref>)</sup> and increased fibrosis, which causes myocardial stiffness and is a characteristic feature of DCM.<sup>(<xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R48">48</xref>)</sup> In human DCM there is an initial adaptive response whereby an increase in collagen fibres boosts growth of the myocardium to enhance contractile force,<sup>(<xref ref-type="bibr" rid="R49">49</xref>)</sup> and this correlates with our proteomic data, showing an increase in collagen-related pathways in mutant mice at 8 weeks. However, over time, this process becomes pathological resulting in impaired cardiomyocyte contractility, causing stiffening of the myocardium, reducing SV and EF until heart failure occurs.</p><p id="P47"><italic>SLC5A6</italic> facilitates the uptake of dietary biotin and pantothenic acid across the cell membrane. Biotin is an essential cofactor for several carboxylases: acetyl-carboxylase (ACC), PCC, MCC and PC. Pantothenic acid is required for the synthesis of CoA.<sup>(<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R27">27</xref>)</sup> The metabolomic analysis of the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mouse hearts confirmed deficiencies in both biotin and pantothenic acid metabolism.</p><p id="P48">Due to the deficiency of biotin, MCC activity, which is required for leucine metabolism, is reduced and the breakdown of 3-methylcrotonyl-CoA occurs via an alternative pathway, leading to the accumulation of C5OH and 3-HIA; metabolites that were elevated in both <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts and in the patients.<sup>(<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R50">50</xref>, <xref ref-type="bibr" rid="R51">51</xref>)</sup> Similarly, PCC catalyses the conversion of propionyl-CoA to methylmalonyl-CoA, which is also a crucial step in the metabolism of BCAA (including isoleucine and valine). PCC deficiency leads to the accumulation of 2-methylcitrate,<sup>(<xref ref-type="bibr" rid="R52">52</xref>)</sup> a metabolite that was elevated in the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mouse hearts. Furthermore, three downregulated pathways identified by proteomic analysis are linked to BCAA catabolism. Additionally, pantothenic acid is converted through a series of steps into CoA. Pantothenic acid itself and two of its downstream derivatives, Phosphopantothenic acid and Phosphopantethein were all decreased in the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mouse hearts.</p><p id="P49">These findings confirm that cardiomyocyte-specific <italic>Slc5a6</italic> deletion disrupts vitamin uptake and mirrors the metabolic abnormalities observed in patients with <italic>SLC5A6</italic> mutations, as well as those with PCC and MCC mutations. Reduced vitamin transport into the heart, therefore, leads to elevated BCAA levels and reduced expression of BCAA catabolism enzymes which have been observed in DCM patients.<sup>(<xref ref-type="bibr" rid="R53">53</xref>)</sup> Enhanced BCAA oxidation in a transverse aortic constriction mouse model improved cardiac function,<sup>(<xref ref-type="bibr" rid="R53">53</xref>)</sup> which supports our hypothesis that biotin and pantothenic acid supplementation could serve as an alternative therapeutic strategy to improve cardiac function by preventing a block in BCAA catabolism.</p><p id="P50">Of the patients with <italic>SLC5A6</italic> mutations reported in the literature, 64% received different combinations of vitamin supplementation at different stages of disease presentation, resulting in clinical improvements.<sup>(<xref ref-type="bibr" rid="R11">11</xref>–<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R23">23</xref>)</sup> In Family 1 reported here, for patient II-1 no vitamin treatment was given and she died from heart failure before the opportunity of a heart transplant arose. Her sibling, patient II-2, vitamin treatment was not initiated until 14 years of age, 7 years after the heart transplant. Modest improvement in development and growth was seen over the past six years, associated with much improved control of her epilepsy. In Family 2,<sup>(<xref ref-type="bibr" rid="R18">18</xref>)</sup> biotin supplementation was initiated 3 weeks after admission for heart failure, and then pantothenic acid was added at day 64, leading progressively to the reversal of the cardiac phenotype and maintained normal cardiac function.</p><p id="P51">To evaluate whether vitamin supplementation could affect disease progression in our <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mouse model, dietary biotin and pantothenic acid were given to the parents before conception and to the pups after weaning. The vitamins were administered at high but safe pharmacological concentrations comparable to doses given to patients,<sup>(<xref ref-type="bibr" rid="R28">28</xref>)</sup> thereby facilitating cellular uptake of vitamins via passive diffusion<sup>(<xref ref-type="bibr" rid="R11">11</xref>)</sup> and bypassing the need for a functional vitamin symporter in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice. Interestingly, in the clinical setting, patient II-5 from Family 2 showed no response to an initial 10mg dose of biotin but experienced rapid clinical improvement following an increase to 15mg, supporting the notion that diffusion-mediated uptake can be therapeutically relevant at higher concentrations. Lipoic acid was not supplemented in our mouse model, as it is synthesized endogenously in the mitochondrial matrix and does not require dietary intake in mammals, unlike biotin and pantothenic acid. Remarkedly, vitamin-supplemented mice were phenotypically normal and showed no evidence of cardiac dysfunction or fibrosis and survived until they were electively culled at the end of the study period (40 weeks). These findings underscore the potential of early high-dose vitamin therapy to mitigate cardiac pathology in the absence of <italic>SLC5A6</italic> function. Future research should explore the effects of initiating treatment at different developmental stages, as this could inform optimal therapeutic windows in humans. Importantly, our findings suggest that incorporating <italic>SLC5A6</italic> into prenatal screening could facilitate early diagnosis and timely intervention, potentially improving long-term clinical outcomes.</p><p id="P52">Previously, there had not been a focused analysis of the heart in patients with SLC5A6 mutations. The results presented here provide a detailed overview of the impact of vitamin loss specifically within the heart on cardiac function and highlights that the underlying initiation of clinical symptoms may be due to a defect in energy metabolism from mitochondrial abnormalities. Imbalances in energy generation or energy use are thought to be key factors in the pathogenesis of DCM<sup>(<xref ref-type="bibr" rid="R43">43</xref>)</sup>, which ultimately leads to heart failure.<sup>(<xref ref-type="bibr" rid="R54">54</xref>)</sup> Given the critical role of mitochondria in energy metabolism, alterations in mitochondrial dynamics and function have been associated with cardiovascular diseases and heart failure.<sup>(<xref ref-type="bibr" rid="R4">4</xref>)</sup> However, it is unknown whether the metabolic energetic dysfunction is a cause or a consequence of disease in DCM. Given the link between the vitamins transported by SMVT and mitochondrial energy metabolism, the morphology of mitochondria was analysed as changes in mitochondrial structure can be a pathological factor in disease progression<sup>(<xref ref-type="bibr" rid="R29">29</xref>)</sup> and alterations are known to be associated with functional deficiencies.<sup>(<xref ref-type="bibr" rid="R30">30</xref>)</sup> In cardiomyocytes, the mitochondria are arranged in a highly ordered arrangement, forming rows parallel to the myofibrils,<sup>(<xref ref-type="bibr" rid="R55">55</xref>)</sup> but this organised assembly is lost in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts. The mitochondrial complexity index (MCI), an indicator of mitochondrial morphology,<sup>(<xref ref-type="bibr" rid="R29">29</xref>)</sup> was considerably increased in the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts by 20 weeks, with increased branching and abnormal donut-shaped mitochondria which are indicative of cellular stress.<sup>(<xref ref-type="bibr" rid="R56">56</xref>)</sup> Mitochondria morphology could be an early indicator of disease onset as smaller yet significant changes in MCI were observed at 8 weeks, alongside the downregulation of key energy metabolism pathways, prior to the onset of an overt DCM phenotype. Interestingly, vitamin supplementation prevented the long-term alterations in mitochondrial morphology in the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts. This was also reflected in proteomic data which showed there was no longer a downregulation in mitochondrial metabolism pathways.</p><p id="P53">Our findings underscore the critical importance of early diagnosis and intervention in <italic>SLC5A6</italic>-related DCM. Vitamin supplementation, when administered early, not only prevents the onset of mitochondrial abnormalities but also halts the progression of DCM, offering a promising therapeutic approach for patients with metabolic-related cardiac diseases. The <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mouse model has proven to be an invaluable tool for unravelling the complex relationship between vitamin transport, mitochondrial energy metabolism, and cardiac dysfunction. These results pave the way for novel strategies focused on enhancing mitochondrial function, such as vitamin supplementation, which could preserve cardiac function by boosting energy metabolism<sup>(<xref ref-type="bibr" rid="R57">57</xref>)</sup> potentially transforming the treatment landscape for DCM and other energy metabolism-related heart conditions.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="EMS206407-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d32aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S17"><title>Acknowledgements</title><p>We would like to thank the Newcastle University Electron Microscopy Unit (grant numbers BB/M012093/1 (Gatan 3View system) and BB/R013942/1 (Hitachi TEM) and in particular Ross Laws. The proteomics data was acquired, processed and analysed at the NUPPA core facility, by both Pawel Palmowski and Andrew Porter. We thank Dr Amy Vincent for her invaluable knowledge and insight regarding mitochondrial structure and function. Guido Bommer for his technical help with the LC-MS-qTOF ion-pairing Agilent analysis. Thanks to Prof Judith Goodship for her work on investigating families with heart disorders which led to the discovery of the mutation. Thanks to MRes students Rania Taufiq, Calum Earl, and Brian Satria for their contribution towards the 3D reconstructions of the mitochondria.</p><sec id="S18"><title>Funding statement</title><p>British Heart Foundation (grant numbers PG/16/105/32659 and PG/24/11744) and PhD studentship from Federated Foundation (Borwick Charitable Trust, Charity Number 291528), all awarded to H.M.P and S.D.B.</p></sec></ack><sec id="S19" sec-type="data-availability"><title>Data availability statement</title><p id="P54">The proteomic data underlying this article are available in MassIVE Repository at <ext-link ext-link-type="uri" xlink:href="https://massive.ucsd.edu/ProteoSAFe/static/massive.jsp">Welcome to MassIVE</ext-link> User: MSV000097747_reviewer. Password: PhillipsH. ftp://MSV000097747@massive-ftp.ucsd.edu</p></sec><fn-group><fn fn-type="conflict" id="FN2"><p id="P55"><bold>Disclosure of interest</bold></p><p id="P56">None declared</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Towbin</surname><given-names>JA</given-names></name><name><surname>Lowe</surname><given-names>AM</given-names></name><name><surname>Colan</surname><given-names>SD</given-names></name><name><surname>Sleeper</surname><given-names>LA</given-names></name><name><surname>Orav</surname><given-names>EJ</given-names></name><name><surname>Clunie</surname><given-names>S</given-names></name><etal/></person-group><article-title>Incidence, causes, and outcomes of dilated cardiomyopathy in children</article-title><source>Jama</source><year>2006</year><volume>296</volume><issue>15</issue><fpage>1867</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">17047217</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garfinkel</surname><given-names>AC</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name></person-group><article-title>Genetic Pathogenesis of Hypertrophic and Dilated Cardiomyopathy</article-title><source>Heart failure clinics</source><year>2018</year><volume>14</volume><issue>2</issue><fpage>139</fpage><lpage>46</lpage><pub-id pub-id-type="pmcid">PMC5851453</pub-id><pub-id pub-id-type="pmid">29525643</pub-id><pub-id pub-id-type="doi">10.1016/j.hfc.2017.12.004</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichart</surname><given-names>D</given-names></name><name><surname>Magnussen</surname><given-names>C</given-names></name><name><surname>Zeller</surname><given-names>T</given-names></name><name><surname>Blankenberg</surname><given-names>S</given-names></name></person-group><article-title>Dilated cardiomyopathy: from epidemiologic to genetic phenotypes: A translational review of current literature</article-title><source>J Intern Med</source><year>2019</year><volume>286</volume><issue>4</issue><fpage>362</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">31132311</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forte</surname><given-names>M</given-names></name><name><surname>Schirone</surname><given-names>L</given-names></name><name><surname>Ameri</surname><given-names>P</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Catalucci</surname><given-names>D</given-names></name><name><surname>Modica</surname><given-names>J</given-names></name><etal/></person-group><article-title>The role of mitochondrial dynamics in cardiovascular diseases</article-title><source>Br J Pharmacol</source><year>2021</year><volume>178</volume><issue>10</issue><fpage>2060</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">32294237</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quick</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name></person-group><article-title>The Sodium/Multivitamin Transporter (SMVT): a Multipotent System With Therapeutic Implications</article-title><source>Vitamins and hormones</source><year>2015</year><volume>98</volume><fpage>63</fpage><lpage>100</lpage><pub-id pub-id-type="pmcid">PMC5530880</pub-id><pub-id pub-id-type="pmid">25817866</pub-id><pub-id pub-id-type="doi">10.1016/bs.vh.2014.12.003</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>PD</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Kekuda</surname><given-names>R</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Fei</surname><given-names>YJ</given-names></name><name><surname>Devoe</surname><given-names>LD</given-names></name><etal/></person-group><article-title>Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitamin transporter mediating the uptake of pantothenate, biotin, and lipoate</article-title><source>The Journal of biological chemistry</source><year>1998</year><volume>273</volume><issue>13</issue><fpage>7501</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9516450</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>JA</given-names></name><name><surname>Feichtinger</surname><given-names>RG</given-names></name><name><surname>Tort</surname><given-names>F</given-names></name><name><surname>Ribes</surname><given-names>A</given-names></name><name><surname>Sperl</surname><given-names>W</given-names></name></person-group><article-title>Lipoic acid biosynthesis defects</article-title><source>J Inherit Metab Dis</source><year>2014</year><volume>37</volume><issue>4</issue><fpage>553</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">24777537</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Said</surname><given-names>HM</given-names></name></person-group><article-title>Intestinal absorption of water-soluble vitamins in health and disease</article-title><source>The Biochemical journal</source><year>2011</year><volume>437</volume><issue>3</issue><fpage>357</fpage><lpage>72</lpage><pub-id pub-id-type="pmcid">PMC4049159</pub-id><pub-id pub-id-type="pmid">21749321</pub-id><pub-id pub-id-type="doi">10.1042/BJ20110326</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosal</surname><given-names>A</given-names></name><name><surname>Lambrecht</surname><given-names>N</given-names></name><name><surname>Subramanya</surname><given-names>SB</given-names></name><name><surname>Kapadia</surname><given-names>R</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name></person-group><article-title>Conditional knockout of the Slc5a6 gene in mouse intestine impairs biotin absorption</article-title><source>American Journal of Physiology-Gastrointestinal and Liver Physiology</source><year>2012</year><volume>304</volume><issue>1</issue><fpage>G64</fpage><lpage>G71</lpage><pub-id pub-id-type="pmcid">PMC3543636</pub-id><pub-id pub-id-type="pmid">23104561</pub-id><pub-id pub-id-type="doi">10.1152/ajpgi.00379.2012</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>NS</given-names></name><name><surname>Kumar</surname><given-names>CK</given-names></name><name><surname>Ortiz</surname><given-names>A</given-names></name><name><surname>Rubin</surname><given-names>SA</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name></person-group><article-title>Molecular mechanism of the intestinal biotin transport process</article-title><source>Am J Physiol</source><year>1999</year><volume>277</volume><issue>4</issue><fpage>C605</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10516089</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>VS</given-names></name><name><surname>Constantinescu</surname><given-names>AR</given-names></name><name><surname>Benke</surname><given-names>PJ</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name></person-group><article-title>Mutations in SLC5A6 associated with brain, immune, bone, and intestinal dysfunction in a young child</article-title><source>Hum Genet</source><year>2017</year><volume>136</volume><issue>2</issue><fpage>253</fpage><lpage>61</lpage><pub-id pub-id-type="pmcid">PMC5263180</pub-id><pub-id pub-id-type="pmid">27904971</pub-id><pub-id pub-id-type="doi">10.1007/s00439-016-1751-x</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname><given-names>AB</given-names></name><name><surname>Arts</surname><given-names>P</given-names></name><name><surname>Polyak</surname><given-names>SW</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>AW</given-names></name><name><surname>Kassahn</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Identification and targeted management of a neurodegenerative disorder caused by biallelic mutations in SLC5A6</article-title><source>NPJ Genom Med</source><year>2019</year><volume>4</volume><fpage>28</fpage><pub-id pub-id-type="pmcid">PMC6856110</pub-id><pub-id pub-id-type="pmid">31754459</pub-id><pub-id pub-id-type="doi">10.1038/s41525-019-0103-x</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwantje</surname><given-names>M</given-names></name><name><surname>de Sain-van der Velden</surname><given-names>M</given-names></name><name><surname>Jans</surname><given-names>J</given-names></name><name><surname>van Gassen</surname><given-names>K</given-names></name><name><surname>Dorrepaal</surname><given-names>C</given-names></name><name><surname>Koop</surname><given-names>K</given-names></name><etal/></person-group><article-title>Genetic defect of the sodium-dependent multivitamin transporter: A treatable disease, mimicking biotinidase deficiency</article-title><source>JIMD Rep</source><year>2019</year><volume>48</volume><issue>1</issue><fpage>11</fpage><lpage>4</lpage><pub-id pub-id-type="pmcid">PMC6606985</pub-id><pub-id pub-id-type="pmid">31392107</pub-id><pub-id pub-id-type="doi">10.1002/jmd2.12040</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holling</surname><given-names>T</given-names></name><name><surname>Nampoothiri</surname><given-names>S</given-names></name><name><surname>Tarhan</surname><given-names>B</given-names></name><name><surname>Schneeberger</surname><given-names>PE</given-names></name><name><surname>Vinayan</surname><given-names>KP</given-names></name><name><surname>Yesodharan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Novel biallelic variants expand the SLC5A6-related phenotypic spectrum</article-title><source>Eur J Hum Genet</source><year>2022</year><volume>30</volume><issue>4</issue><fpage>439</fpage><lpage>49</lpage><pub-id pub-id-type="pmcid">PMC8747999</pub-id><pub-id pub-id-type="pmid">35013551</pub-id><pub-id pub-id-type="doi">10.1038/s41431-021-01033-2</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauth</surname><given-names>I</given-names></name><name><surname>Waterham</surname><given-names>HR</given-names></name><name><surname>Wanders</surname><given-names>RJA</given-names></name><name><surname>van der Crabben</surname><given-names>SN</given-names></name><name><surname>van Karnebeek</surname><given-names>CDM</given-names></name></person-group><article-title>A mild case of sodium-dependent multivitamin transporter (SMVT) deficiency illustrating the importance of treatment response in variant classification</article-title><source>Cold Spring Harb Mol Case Stud</source><year>2022</year><volume>8</volume><issue>2</issue><pub-id pub-id-type="pmcid">PMC8958925</pub-id><pub-id pub-id-type="pmid">35217562</pub-id><pub-id pub-id-type="doi">10.1101/mcs.a006185</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsuno</surname><given-names>Y</given-names></name><name><surname>Hamada</surname><given-names>K</given-names></name><name><surname>Hamanaka</surname><given-names>K</given-names></name><name><surname>Miyoshi</surname><given-names>K</given-names></name><name><surname>Tsuchimoto</surname><given-names>K</given-names></name><name><surname>Sunada</surname><given-names>S</given-names></name><etal/></person-group><article-title>Novel missense variants cause intermediate phenotypes in the phenotypic spectrum of SLC5A6-related disorders</article-title><source>J Hum Genet</source><year>2024</year><volume>69</volume><issue>2</issue><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">38012394</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montomoli</surname><given-names>M</given-names></name><name><surname>Vetro</surname><given-names>A</given-names></name><name><surname>Tubili</surname><given-names>F</given-names></name><name><surname>Donati</surname><given-names>MA</given-names></name><name><surname>Daniotti</surname><given-names>M</given-names></name><name><surname>Pochiero</surname><given-names>F</given-names></name><etal/></person-group><article-title>A novel SLC5A6 homozygous variant in a family with multivitamin-dependent neurometabolic disorder: Phenotype expansion and long-term follow-up</article-title><source>Eur J Med Genet</source><year>2023</year><volume>66</volume><issue>8</issue><elocation-id>104808</elocation-id><pub-id pub-id-type="pmid">37391029</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Vyve</surname><given-names>FX</given-names></name><name><surname>Mercier</surname><given-names>N</given-names></name><name><surname>Papadopoulos</surname><given-names>J</given-names></name><name><surname>Heijmans</surname><given-names>C</given-names></name><name><surname>Dessy</surname><given-names>H</given-names></name><name><surname>Monestier</surname><given-names>O</given-names></name><etal/></person-group><article-title>A new case of sodium-dependent multivitamin transporter defect occurring as a life-threatening condition responsive to early vitamin supplementation and literature review</article-title><source>Mol Genet Genomic Med</source><year>2024</year><volume>12</volume><issue>2</issue><elocation-id>e2388</elocation-id><pub-id pub-id-type="pmcid">PMC10847706</pub-id><pub-id pub-id-type="pmid">38407570</pub-id><pub-id pub-id-type="doi">10.1002/mgg3.2388</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupasinghe</surname><given-names>K</given-names></name><name><surname>Onyeador</surname><given-names>N</given-names></name></person-group><article-title>Sodium-dependent multivitamin transporter defects: a rare cause of recurrent vomiting and faltering growth</article-title><source>Frontline Gastroenterol</source><year>2023</year><volume>14</volume><issue>4</issue><fpage>346</fpage><lpage>9</lpage><pub-id pub-id-type="pmcid">PMC11138166</pub-id><pub-id pub-id-type="pmid">37409333</pub-id><pub-id pub-id-type="doi">10.1136/flgastro-2022-102344</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansour-Hendili</surname><given-names>L</given-names></name><name><surname>Gitiaux</surname><given-names>C</given-names></name><name><surname>Harion</surname><given-names>M</given-names></name><name><surname>Latouche</surname><given-names>C</given-names></name><name><surname>Heron</surname><given-names>B</given-names></name><name><surname>Stojkovic</surname><given-names>T</given-names></name><etal/></person-group><article-title>Recurrent ‘outsider’ intronic variation in the SLC5A6 gene causes severe mixed axonal and demyelinating neuropathy, cyclic vomiting and optic atrophy in 3 families from Maghreb</article-title><source>Front Genet</source><year>2024</year><volume>15</volume><elocation-id>1352006</elocation-id><pub-id pub-id-type="pmcid">PMC10859498</pub-id><pub-id pub-id-type="pmid">38348452</pub-id><pub-id pub-id-type="doi">10.3389/fgene.2024.1352006</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>LG</given-names></name><name><surname>Sabui</surname><given-names>S</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name><name><surname>Niaz</surname><given-names>A</given-names></name><name><surname>Girisha</surname><given-names>KM</given-names></name><name><surname>Radhakrishnan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Genome sequencing enables diagnosis and treatment of SLC5A6 neuropathy</article-title><source>Eur J Hum Genet</source><year>2024</year><volume>32</volume><issue>8</issue><fpage>947</fpage><lpage>53</lpage><pub-id pub-id-type="pmcid">PMC11291669</pub-id><pub-id pub-id-type="pmid">38816490</pub-id><pub-id pub-id-type="doi">10.1038/s41431-024-01641-8</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walimbe</surname><given-names>AS</given-names></name><name><surname>Waskow</surname><given-names>E</given-names></name><name><surname>Mackay</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Gijavanekar</surname><given-names>C</given-names></name><name><surname>Difalco</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Expanded Clinical Phenotype and the Role of Untargeted Metabolomics Analysis in Confirming the Diagnosis of Sodium-Dependent Multivitamin Transporter Deficiency</article-title><source>Am J Med Genet A</source><year>2025</year><elocation-id>e64014</elocation-id><pub-id pub-id-type="pmid">39898461</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Sung</surname><given-names>HH</given-names></name><name><surname>Huang</surname><given-names>YF</given-names></name><name><surname>Ding</surname><given-names>YS</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Novel SLC5A6 mutations lead to B lymphocyte maturation defects with metabolic abnormality rescuable by biotin replenishment</article-title><source>Clin Immunol</source><year>2023</year><volume>257</volume><elocation-id>109855</elocation-id><pub-id pub-id-type="pmid">38036278</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mock</surname><given-names>NI</given-names></name><name><surname>Malik</surname><given-names>MI</given-names></name><name><surname>Stumbo</surname><given-names>PJ</given-names></name><name><surname>Bishop</surname><given-names>WP</given-names></name><name><surname>Mock</surname><given-names>DM</given-names></name></person-group><article-title>Increased urinary excretion of 3-hydroxyisovaleric acid and decreased urinary excretion of biotin are sensitive early indicators of decreased biotin status in experimental biotin deficiency</article-title><source>Am J Clin Nutr</source><year>1997</year><volume>65</volume><issue>4</issue><fpage>951</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9094878</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname><given-names>TD</given-names></name><name><surname>Matthews</surname><given-names>NI</given-names></name><name><surname>Stratton</surname><given-names>SL</given-names></name><name><surname>Mock</surname><given-names>DM</given-names></name><name><surname>Boysen</surname><given-names>G</given-names></name></person-group><article-title>Measurement of 3 - hydroxyisovaleric acid in urine from marginally biotin-deficient humans by UPLC-MS/MS</article-title><source>Anal Bioanal Chem</source><year>2011</year><volume>401</volume><issue>9</issue><fpage>2805</fpage><lpage>10</lpage><pub-id pub-id-type="pmcid">PMC3628633</pub-id><pub-id pub-id-type="pmid">21892638</pub-id><pub-id pub-id-type="doi">10.1007/s00216-011-5356-x</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahiliani</surname><given-names>AG</given-names></name><name><surname>Beinlich</surname><given-names>CJ</given-names></name></person-group><article-title>Pantothenic acid in health and disease</article-title><source>Vitam Horm</source><year>1991</year><volume>46</volume><fpage>165</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">1746161</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>RJ</given-names></name></person-group><article-title>Biotin in metabolism and molecular biology</article-title><source>Annu Rev Nutr</source><year>2002</year><volume>22</volume><fpage>221</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">12055344</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>AB</given-names></name><name><surname>Jacob</surname><given-names>S</given-names></name></person-group><article-title>A simple practice guide for dose conversion between animals and human</article-title><source>J Basic Clin Pharm</source><year>2016</year><volume>7</volume><issue>2</issue><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="pmcid">PMC4804402</pub-id><pub-id pub-id-type="pmid">27057123</pub-id><pub-id pub-id-type="doi">10.4103/0976-0105.177703</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>BC</given-names></name><name><surname>Neikirk</surname><given-names>K</given-names></name><name><surname>Katti</surname><given-names>P</given-names></name><name><surname>Claypool</surname><given-names>SM</given-names></name><name><surname>Kirabo</surname><given-names>A</given-names></name><name><surname>McReynolds</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Mitochondria in disease: changes in shapes and dynamics</article-title><source>Trends Biochem Sci</source><year>2024</year><volume>49</volume><issue>4</issue><fpage>346</fpage><lpage>60</lpage><pub-id pub-id-type="pmcid">PMC10997448</pub-id><pub-id pub-id-type="pmid">38402097</pub-id><pub-id pub-id-type="doi">10.1016/j.tibs.2024.01.011</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vue</surname><given-names>Z</given-names></name><name><surname>Neikirk</surname><given-names>K</given-names></name><name><surname>Vang</surname><given-names>L</given-names></name><name><surname>Garza-Lopez</surname><given-names>E</given-names></name><name><surname>Christensen</surname><given-names>TA</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Three-dimensional mitochondria reconstructions of murine cardiac muscle changes in size across aging</article-title><source>American journal of physiology Heart and circulatory physiology</source><year>2023</year><volume>325</volume><issue>5</issue><fpage>H965</fpage><lpage>H82</lpage><pub-id pub-id-type="pmcid">PMC10977873</pub-id><pub-id pub-id-type="pmid">37624101</pub-id><pub-id pub-id-type="doi">10.1152/ajpheart.00202.2023</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowling</surname><given-names>RT</given-names></name><name><surname>Kupsky</surname><given-names>D</given-names></name><name><surname>Kahn</surname><given-names>AM</given-names></name><name><surname>Daniels</surname><given-names>LB</given-names></name><name><surname>Greenberg</surname><given-names>BH</given-names></name></person-group><article-title>Mechanisms of cardiac collagen deposition in experimental models and human disease</article-title><source>Transl Res</source><year>2019</year><volume>209</volume><fpage>138</fpage><lpage>55</lpage><pub-id pub-id-type="pmcid">PMC6996650</pub-id><pub-id pub-id-type="pmid">30986384</pub-id><pub-id pub-id-type="doi">10.1016/j.trsl.2019.03.004</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>F</given-names></name><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis</article-title><source>Signal Transduct Target Ther</source><year>2024</year><volume>9</volume><issue>1</issue><fpage>133</fpage><pub-id pub-id-type="pmcid">PMC11094072</pub-id><pub-id pub-id-type="pmid">38744811</pub-id><pub-id pub-id-type="doi">10.1038/s41392-024-01816-1</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinvalet</surname><given-names>D</given-names></name><name><surname>Dykxhoorn</surname><given-names>DM</given-names></name><name><surname>Ferrini</surname><given-names>R</given-names></name><name><surname>Lieberman</surname><given-names>J</given-names></name></person-group><article-title>Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death</article-title><source>Cell</source><year>2008</year><volume>133</volume><issue>4</issue><fpage>681</fpage><lpage>92</lpage><pub-id pub-id-type="pmcid">PMC2840390</pub-id><pub-id pub-id-type="pmid">18485875</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2008.03.032</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores</surname><given-names>JJ</given-names></name><name><surname>Klebe</surname><given-names>D</given-names></name><name><surname>Rolland</surname><given-names>WB</given-names></name><name><surname>Lekic</surname><given-names>T</given-names></name><name><surname>Krafft</surname><given-names>PR</given-names></name><name><surname>Zhang</surname><given-names>JH</given-names></name></person-group><article-title>PPARgamma-induced upregulation of CD36 enhances hematoma resolution and attenuates long-term neurological deficits after germinal matrix hemorrhage in neonatal rats</article-title><source>Neurobiol Dis</source><year>2016</year><volume>87</volume><fpage>124</fpage><lpage>33</lpage><pub-id pub-id-type="pmcid">PMC4724557</pub-id><pub-id pub-id-type="pmid">26739391</pub-id><pub-id pub-id-type="doi">10.1016/j.nbd.2015.12.015</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopaschuk</surname><given-names>GD</given-names></name><name><surname>Karwi</surname><given-names>QG</given-names></name><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Wende</surname><given-names>AR</given-names></name><name><surname>Abel</surname><given-names>ED</given-names></name></person-group><article-title>Cardiac Energy Metabolism in Heart Failure</article-title><source>Circulation research</source><year>2021</year><volume>128</volume><issue>10</issue><fpage>1487</fpage><lpage>513</lpage><pub-id pub-id-type="pmcid">PMC8136750</pub-id><pub-id pub-id-type="pmid">33983836</pub-id><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.318241</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edhouse</surname><given-names>J</given-names></name><name><surname>Thakur</surname><given-names>RK</given-names></name><name><surname>Khalil</surname><given-names>JM</given-names></name></person-group><article-title>ABC of clinical electrocardiography. Conditions affecting the left side of the heart</article-title><source>BMJ</source><year>2002</year><volume>324</volume><issue>7348</issue><fpage>1264</fpage><lpage>7</lpage><pub-id pub-id-type="pmcid">PMC1123219</pub-id><pub-id pub-id-type="pmid">12028984</pub-id><pub-id pub-id-type="doi">10.1136/bmj.324.7348.1264</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francone</surname><given-names>M</given-names></name></person-group><article-title>Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance</article-title><source>ISRN Radiol</source><year>2014</year><volume>2014</volume><elocation-id>365404</elocation-id><pub-id pub-id-type="pmcid">PMC4045555</pub-id><pub-id pub-id-type="pmid">24967294</pub-id><pub-id pub-id-type="doi">10.1155/2014/365404</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultheiss</surname><given-names>HP</given-names></name><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Caforio</surname><given-names>ALP</given-names></name><name><surname>Escher</surname><given-names>F</given-names></name><name><surname>Hershberger</surname><given-names>RE</given-names></name><name><surname>Lipshultz</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Dilated cardiomyopathy</article-title><source>Nat Rev Dis Primers</source><year>2019</year><volume>5</volume><issue>1</issue><fpage>32</fpage><pub-id pub-id-type="pmcid">PMC7096917</pub-id><pub-id pub-id-type="pmid">31073128</pub-id><pub-id pub-id-type="doi">10.1038/s41572-019-0084-1</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>AM</given-names></name><name><surname>Jefferies</surname><given-names>JL</given-names></name><name><surname>Rossano</surname><given-names>JW</given-names></name><name><surname>Decker</surname><given-names>JA</given-names></name><name><surname>Cannon</surname><given-names>BC</given-names></name><name><surname>Kim</surname><given-names>JJ</given-names></name></person-group><article-title>Electrocardiographic abnormalities and arrhythmias are strongly associated with the development of cardiomyopathy in muscular dystrophy</article-title><source>Heart Rhythm</source><year>2010</year><volume>7</volume><issue>10</issue><fpage>1484</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20601155</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finocchiaro</surname><given-names>G</given-names></name><name><surname>Merlo</surname><given-names>M</given-names></name><name><surname>Sheikh</surname><given-names>N</given-names></name><name><surname>De Angelis</surname><given-names>G</given-names></name><name><surname>Papadakis</surname><given-names>M</given-names></name><name><surname>Olivotto</surname><given-names>I</given-names></name><etal/></person-group><article-title>The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy</article-title><source>European journal of heart failure</source><year>2020</year><volume>22</volume><issue>7</issue><fpage>1097</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">32243666</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soliman</surname><given-names>EZ</given-names></name><name><surname>Rautaharju</surname><given-names>PM</given-names></name></person-group><article-title>Heart rate adjustment of PR interval in middle-aged and older adults</article-title><source>J Electrocardiol</source><year>2012</year><volume>45</volume><issue>1</issue><fpage>66</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21784432</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riehle</surname><given-names>C</given-names></name><name><surname>Bauersachs</surname><given-names>J</given-names></name></person-group><article-title>Small animal models of heart failure</article-title><source>Cardiovascular research</source><year>2019</year><volume>115</volume><issue>13</issue><fpage>1838</fpage><lpage>49</lpage><pub-id pub-id-type="pmcid">PMC6803815</pub-id><pub-id pub-id-type="pmid">31243437</pub-id><pub-id pub-id-type="doi">10.1093/cvr/cvz161</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaccini</surname><given-names>D</given-names></name><name><surname>Montoya-Uribe</surname><given-names>V</given-names></name><name><surname>Aan</surname><given-names>FJ</given-names></name><name><surname>Modesti</surname><given-names>L</given-names></name><name><surname>Potes</surname><given-names>Y</given-names></name><name><surname>Wieckowski</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Mitochondrial Function and Dysfunction in Dilated Cardiomyopathy</article-title><source>Front Cell Dev Biol</source><year>2020</year><volume>8</volume><elocation-id>624216</elocation-id><pub-id pub-id-type="pmcid">PMC7835522</pub-id><pub-id pub-id-type="pmid">33511136</pub-id><pub-id pub-id-type="doi">10.3389/fcell.2020.624216</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirkx</surname><given-names>E</given-names></name><name><surname>da Costa Martins</surname><given-names>PA</given-names></name><name><surname>De Windt</surname><given-names>LJ</given-names></name></person-group><article-title>Regulation of fetal gene expression in heart failure</article-title><source>Biochim Biophys Acta</source><year>2013</year><volume>1832</volume><issue>12</issue><fpage>2414</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">24036209</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakao</surname><given-names>K</given-names></name><name><surname>Minobe</surname><given-names>W</given-names></name><name><surname>Roden</surname><given-names>R</given-names></name><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Leinwand</surname><given-names>LA</given-names></name></person-group><article-title>Myosin heavy chain gene expression in human heart failure</article-title><source>The Journal of clinical investigation</source><year>1997</year><volume>100</volume><issue>9</issue><fpage>2362</fpage><lpage>70</lpage><pub-id pub-id-type="pmcid">PMC508434</pub-id><pub-id pub-id-type="pmid">9410916</pub-id><pub-id pub-id-type="doi">10.1172/JCI119776</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>WT</given-names></name><name><surname>Gilbert</surname><given-names>EM</given-names></name><name><surname>Lowes</surname><given-names>BD</given-names></name><name><surname>Minobe</surname><given-names>WA</given-names></name><name><surname>Larrabee</surname><given-names>P</given-names></name><name><surname>Roden</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype</article-title><source>Mol Med</source><year>2002</year><volume>8</volume><issue>11</issue><fpage>750</fpage><lpage>60</lpage><pub-id pub-id-type="pmcid">PMC2039952</pub-id><pub-id pub-id-type="pmid">12520092</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brower</surname><given-names>GL</given-names></name><name><surname>Janicki</surname><given-names>JS</given-names></name></person-group><article-title>Contribution of ventricular remodeling to pathogenesis of heart failure in rats</article-title><source>American journal of physiology Heart and circulatory physiology</source><year>2001</year><volume>280</volume><issue>2</issue><fpage>H674</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11158966</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azevedo</surname><given-names>PS</given-names></name><name><surname>Polegato</surname><given-names>BF</given-names></name><name><surname>Minicucci</surname><given-names>MF</given-names></name><name><surname>Paiva</surname><given-names>SA</given-names></name><name><surname>Zornoff</surname><given-names>LA</given-names></name></person-group><article-title>Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment</article-title><source>Arq Bras Cardiol</source><year>2016</year><volume>106</volume><issue>1</issue><fpage>62</fpage><lpage>9</lpage><pub-id pub-id-type="pmcid">PMC4728597</pub-id><pub-id pub-id-type="pmid">26647721</pub-id><pub-id pub-id-type="doi">10.5935/abc.20160005</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>KT</given-names></name></person-group><article-title>Cardiac interstitium in health and disease: the fibrillar collagen network</article-title><source>Journal of the American College of Cardiology</source><year>1989</year><volume>13</volume><issue>7</issue><fpage>1637</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">2656824</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallardo</surname><given-names>ME</given-names></name><name><surname>Desviat</surname><given-names>LR</given-names></name><name><surname>Rodriguez</surname><given-names>JM</given-names></name><name><surname>Esparza-Gordillo</surname><given-names>J</given-names></name><name><surname>Perez-Cerda</surname><given-names>C</given-names></name><name><surname>Perez</surname><given-names>B</given-names></name><etal/></person-group><article-title>The molecular basis of 3-methylcrotonylglycinuria, a disorder of leucine catabolism</article-title><source>Am J Hum Genet</source><year>2001</year><volume>68</volume><issue>2</issue><fpage>334</fpage><lpage>46</lpage><pub-id pub-id-type="pmcid">PMC1235267</pub-id><pub-id pub-id-type="pmid">11170888</pub-id><pub-id pub-id-type="doi">10.1086/318202</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Mutairi</surname><given-names>F</given-names></name><name><surname>Alkhalaf</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>AR</given-names></name><name><surname>Al Othaim</surname><given-names>A</given-names></name><name><surname>Alfadhel</surname><given-names>M</given-names></name></person-group><article-title>Outcomes of cases with elevated 3-hydroxyisovaleryl carnitine report from the newborn screening program</article-title><source>Mol Genet Metab Rep</source><year>2024</year><volume>41</volume><elocation-id>101153</elocation-id><pub-id pub-id-type="pmcid">PMC11525625</pub-id><pub-id pub-id-type="pmid">39484073</pub-id><pub-id pub-id-type="doi">10.1016/j.ymgmr.2024.101153</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wongkittichote</surname><given-names>P</given-names></name><name><surname>Mew</surname><given-names>Ah</given-names></name><name><surname>Chapman</surname><given-names>KA</given-names></name></person-group><article-title>Propionyl-CoA carboxylase - A review</article-title><source>Molecular genetics and metabolism</source><year>2017</year><volume>122</volume><issue>4</issue><fpage>145</fpage><lpage>52</lpage><pub-id pub-id-type="pmcid">PMC5725275</pub-id><pub-id pub-id-type="pmid">29033250</pub-id><pub-id pub-id-type="doi">10.1016/j.ymgme.2017.10.002</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uddin</surname><given-names>GM</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Fukushima</surname><given-names>A</given-names></name><name><surname>Wagg</surname><given-names>CS</given-names></name><name><surname>Gopal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure</article-title><source>Cardiovasc Diabetol</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>86</fpage><pub-id pub-id-type="pmcid">PMC6610921</pub-id><pub-id pub-id-type="pmid">31277657</pub-id><pub-id pub-id-type="doi">10.1186/s12933-019-0892-3</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Tian</surname><given-names>R</given-names></name></person-group><article-title>Mitochondrial dysfunction in pathophysiology of heart failure</article-title><source>The Journal of clinical investigation</source><year>2018</year><volume>128</volume><issue>9</issue><fpage>3716</fpage><lpage>26</lpage><pub-id pub-id-type="pmcid">PMC6118589</pub-id><pub-id pub-id-type="pmid">30124471</pub-id><pub-id pub-id-type="doi">10.1172/JCI120849</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoppel</surname><given-names>CL</given-names></name><name><surname>Tandler</surname><given-names>B</given-names></name><name><surname>Fujioka</surname><given-names>H</given-names></name><name><surname>Riva</surname><given-names>A</given-names></name></person-group><article-title>Dynamic organization of mitochondria in human heart and in myocardial disease</article-title><source>The international journal of biochemistry &amp; cell biology</source><year>2009</year><volume>41</volume><issue>10</issue><fpage>1949</fpage><lpage>56</lpage><pub-id pub-id-type="pmcid">PMC3221317</pub-id><pub-id pub-id-type="pmid">19446651</pub-id><pub-id pub-id-type="doi">10.1016/j.biocel.2009.05.004</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Aggarwal</surname><given-names>K</given-names></name><name><surname>Pattnaik</surname><given-names>B</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Sethi</surname><given-names>T</given-names></name><name><surname>Tiwari</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Computational classification of mitochondrial shapes reflects stress and redox state</article-title><source>Cell Death Dis</source><year>2013</year><volume>4</volume><issue>1</issue><fpage>e461</fpage><pub-id pub-id-type="pmcid">PMC3564000</pub-id><pub-id pub-id-type="pmid">23328668</pub-id><pub-id pub-id-type="doi">10.1038/cddis.2012.213</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piquereau</surname><given-names>J</given-names></name><name><surname>Boitard</surname><given-names>SE</given-names></name><name><surname>Ventura-Clapier</surname><given-names>R</given-names></name><name><surname>Mericskay</surname><given-names>M</given-names></name></person-group><article-title>Metabolic Therapy of Heart Failure: Is There a Future for B Vitamins?</article-title><source>Int J Mol Sci</source><year>2021</year><volume>23</volume><issue>1</issue><pub-id pub-id-type="pmcid">PMC8744601</pub-id><pub-id pub-id-type="pmid">35008448</pub-id><pub-id pub-id-type="doi">10.3390/ijms23010030</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" orientation="portrait" position="float"><caption><title>Translational perspective</title></caption><p>This study highlights the therapeutic potential of vitamin supplementation in treating dilated cardiomyopathy (DCM) caused by mitochondrial abnormalities. Using a cardiac-specific <italic>Slc5a6</italic> knockout mouse model, we demonstrated that deficiencies in key vitamins, biotin and pantothenic acid, impair mitochondrial energy metabolism, leading to DCM progression. Remarkably, vitamin supplementation preserved cardiac function, morphology, and survival, suggesting that restoring vitamin levels could be a promising therapeutic strategy for DCM and other cardiomyopathies linked to metabolic deficiencies. These findings could inform newborn screening programmes and clinical approaches for treating mitochondrial-related cardiac diseases by targeting specific vitamin deficiencies.</p></boxed-text><boxed-text id="BX2" orientation="portrait" position="float"><sec id="S20"><title>Key Question</title><p>What is the underlying molecular cause of early-onset dilated cardiomyopathy in patients with <italic>SLC5A6</italic> mutations, and can insights from a cardiac-specific knockout mouse model reveal potential metabolic mechanisms and therapeutic strategies involving vitamin supplementation?</p></sec><sec id="S21"><title>Key Finding</title><p>Cardiac-specific deletion of <italic>Slc5a6</italic> in mice caused early mitochondrial dysfunction, metabolic derangement, and progressive dilated cardiomyopathy. Strikingly, early and continuous supplementation with biotin and pantothenic acid completely preserved cardiac structure, function, and survival, paralleling successful outcomes in patients treated early.</p></sec><sec id="S22"><title>Take Home Message</title><p>This study establishes a mechanistic link between <italic>SLC5A6</italic> mutations, vitamin deficiency and mitochondrial abnormalities as a cause of dilated cardiomyopathy. Early vitamin supplementation prevents disease onset, highlighting the potential of targeted vitamin therapy in metabolic cardiomyopathies.</p></sec></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title>Clinical presentation and modelling of <italic>SLC5A6</italic><sup><italic>R253W</italic></sup> mutation</title><p>(A) Pedigree of Family 1. The unaffected consanguineous parents and child II-3 were heterozygous for the <italic>SLC5A6</italic> mutation (G/A), whereas children II-1 and II-2 both had DCM and were homozygous (A/A). (B-G) Imaging of a left ventricular heart biopsy from child II-2. (B,C) Myocardial disarray with hypertrophied cardiomyocytes (black arrowheads), hyperchromatic nuclei (green arrowheads) and interstitial fibrosis (blue arrowheads). (D-G) Sarcomeric wasting (black arrow in D), sarcomeric disarray (blue arrow in D), Z band disarray (black arrowheads in D), fragmented mitochondria (black arrowheads in E,F) and mitochondrial degradation (red arrowheads in E,G). (H) Amino acid residue R253 is highly conserved across species. (I) Schematic of SMVT. The patient mutation, R253W, is in the hinge region of the transporter. (J-N) Protein modelling of SMVT with R253 indicated (J). When changed to R253W (K), a salt bridge (orange) is removed (black arrow in M,N). Scale bars B,C = 20µm, D = 2µm, E-G = 500nm.</p></caption><graphic xlink:href="EMS206407-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Cardiac-specific <italic>Slc5a6</italic> KO (<italic>Slc5a6</italic><sup><italic>cKO</italic></sup>) mouse recapitulates DCM phenotype</title><p>(A,B) Hearts from E15.5 control embryos (A) were comparable with <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutant embryos (B). (C-F) <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutant hearts collected at 26 weeks were visibly larger and dilated (D) with ventricular and atrial enlargement (F) compared to a controls (C,E). (G,H) WGA staining was performed on coronal heart sections of 14-week control (G) and <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutant hearts (H). (I) Cardiomyocytes were significantly larger in both ventricles in the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutant (<italic>n</italic>=4) compared to the control (<italic>n</italic>=6) hearts (cell area measured from four regions of interest per ventricle with three technical repeats per heart). (J) No difference in heart weight (HW) to body weight (BW) ratio was observed between control (<italic>n</italic>=8) and <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutant (<italic>n</italic>=6) mice at 20 weeks. (K-P) Fibrosis was increased in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutant hearts (<italic>n</italic>=3; L,M) compared to control hearts (<italic>n</italic>=3; K,M) at 20 weeks. (N-P) Following vitamin supplementation, no increase in fibrosis in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants (<italic>n</italic>=3) compared to control (<italic>n</italic>=3) mice was observed. Data are represented as mean ± SEM. ns = nonsignificant, **p &lt; 0.01, ***p &lt; 0.001 by one-way ANOVA with Bonferroni correction for multiple comparisons or unpaired t-test for two sample comparisons. RV, right ventricle; LV, left ventricle; RA, right atria; LA, left atria. Con, control; cKO, <italic>Slc5a6</italic><sup><italic>cKO</italic></sup>; ConV, vitamin-supplemented control; cKOV, vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup>. Scale bars A,B = 500µm, C,D = 2mm, E,F = 1mm, G,H = 50µm, K,L,N,O = 100µm.</p></caption><graphic xlink:href="EMS206407-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Vitamin supplementation prevents cardiac function defects in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutant mice</title><p>(A-F) CMR imaging at 20 weeks. A significant decrease in ejection fraction (A), stroke volume (B) and cardiac output (C) was observed in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants (<italic>n</italic>=4) compared to controls (<italic>n</italic>=6). (D-F) After vitamin supplementation, no apparent differences in cardiac function was seen (<italic>n</italic>=2 for each genotype). (G-J) Representative ECG traces from 20-week mice. Control (G) and vitamin-supplemented control (H) mice have well-defined P, QRS and ST parameters whereas <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice (I) present with an undefined and relatively flat trace, with loss or reduction of the P wave and an undefined ST wave (arrows). ECG traces from vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants (J) were comparable to control mice. (K,L) The PR interval was measured and was significantly longer in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> compared to control mice. No difference was observed in vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice at 8 and 40 weeks (K,L; 8 weeks: Con <italic>n</italic>=12, cKO <italic>n</italic>=10, ConV <italic>n</italic>=12, cKOV <italic>n</italic>=6; 40 weeks: Con <italic>n</italic>=8, ConV <italic>n</italic>=7, cKOV <italic>n</italic>=6). (M) The heart rate was significantly lower in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice at 8 weeks (<italic>n</italic>=17) compared to controls (<italic>n</italic>=13) and no differences were seen in vitamin-supplemented mice (ConV <italic>n</italic>=12 and cKOV <italic>n</italic>=10). (N) Longitudinal measurements illustrated the heart rate of <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice was consistently lower than control and vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice. Con, control; cKO, <italic>Slc5a6</italic><sup><italic>cKO</italic></sup>; ConV, vitamin-supplemented control; cKOV, vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup>. Data are represented as mean ± SEM. ns = nonsignificant, **p &lt; 0.01, ***p &lt; 0.001 by one-way ANOVA with Bonferroni correction for multiple comparisons or unpaired t-test for two sample comparisons.</p></caption><graphic xlink:href="EMS206407-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Reduced vitamin transport in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts</title><p>(A-G) Acylcarnitine analysis of plasma showed a significant increase in C5OH in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants (<italic>n</italic>=6) compared to controls (<italic>n</italic>=6). Metabolic analysis of heart powder showed significant changes in 3HIA, 2MCA, PA, PPA, PP and CoAG in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants (<italic>n</italic>=5) compared to controls (<italic>n</italic>=6). (H-Q) A decrease in PCC/MCC biotinylation was observed in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants at 5 and 20 weeks (H,J), with no corresponding difference in liver samples (I,K). In vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants PCC/MCC biotinylation levels were comparable to control levels (L). No change in PC was observed in the hearts or livers (M-Q). Data are represented as mean ± SEM. ns, nonsignificant, *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001 by one-way ANOVA with Bonferroni correction for multiple comparisons or unpaired t-test for two sample comparisons. C5OH, 3-hydroxyisovaleryl-carnitine; 3-HIA, 3-hydroxyisovaleric acid; 2MCA, 2-methylcitric acid; PA, pantothenic acid; PPA, phosphopantothenic acid; PP, phosphopantethein; CoAG, CoA-glutathione; Con, control; cKO, <italic>Slc5a6</italic><sup><italic>cKO</italic></sup>; ConV, vitamin-supplemented control; cKOV, vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup>.</p></caption><graphic xlink:href="EMS206407-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Increased mitochondria complexity following loss of <italic>Slc5a6</italic> is prevented by vitamin supplementation</title><p>(A-H) Mitochondria imaging at 20 weeks by TEM (A,B,E,F) and 3D reconstructions (C,D,G,H). Mitochondria in controls, vitamin-supplemented controls and vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts were all comparable (A,C,E-H) whereas mitochondria in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts (B,D) were unevenly arranged and irregularly shaped with evidence of mitochondrial degradation (arrows in B). Representative individual mitochondria of the minimum (min), first quartile (1Q), median (med), third quartile (3Q) and maximum (max) MCI are shown (total number of mitochondria analysed: Con = 468, cKO = 530, ConV = 241 and cKOV = 240). (I-L) The MCI was significantly increased in 20-week <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice on a normal diet (I) and the mitochondrial volume was significantly decreased (J). Bivariate analysis of MCI:volume shows a significant difference in the regression line (K) and the cumulative frequency distribution curves do not overlap (L). (M-P) In vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice the MCI was significantly reduced (M) and there was no difference in mitochondrial volume (N) and complexity (O,P). Data are represented as mean ± SEM. ns, nonsignificant, ***p &lt; 0.01, ****p &lt; 0.0001, by unpaired t-test for two sample comparisons. Con, control; cKO, <italic>Slc5a6</italic><sup><italic>cKO</italic></sup>; ConV, vitamin-supplemented control; cKOV, vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup>. Scale bars A,B,E,F = 500nm, C,D,G,H = 1µm.</p></caption><graphic xlink:href="EMS206407-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Proteomic analysis revealed altered metabolism and increased fibrosis correlate with early indicators of DCM in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice</title><p>(A-E) Proteomic analysis at 8 weeks. PCA plot (A) and heatmap (B) illustrate that the proteome of the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants was distinct from the three other groups (control, vitamin-supplemented control and vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts; <italic>n</italic>=5 per group). (C,D) Volcano plots showing proteins with a significant (q&lt;0.05) fold change. (C) Under a normal diet, 1459 proteins with a fold change of ≤-0.5 and ≥0.5 (red dots) and 478 proteins with a fold change of &gt;-0.5 and &lt;0.5 (blue dots). (D) With vitamin supplementation only 153 proteins with a fold change of ≤-0.5 and ≥0.5 (orange dots) and 179 proteins with a fold change of &gt;-0.5 and &lt;0.5 (green dots) were seen. (E) Venn diagram illustrating 124 of the proteins with a fold change of ≤-0.5 and ≥0.5, remained significantly differentially expressed following vitamin supplementation. (F,G) IPA analysis of up- and down-regulated proteins. For the mice on a normal diet, the majority of the enriched down-regulated pathways in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutant mice are linked to different components of the energy metabolism pathways in mitochondria (asterisks) (F). In comparison, vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutant mice only had downregulation of peroxisome-related pathways (G). (H-M) Correlation graphs of proteins involved in fatty acid β-oxidation (H-J) or collagen biosynthesis (K-M) (red dots) illustrate the shift away from the line of best fit in the <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants (circled dots), which shift back to the line following vitamin supplementation.</p></caption><graphic xlink:href="EMS206407-f006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><title>Decreased energy metabolism pathways and the defective electron transport chain in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice</title><p>(A) Summary of five different pathways involved in energy metabolism identified in the proteomics analysis of 8-week hearts. The majority of proteins in the TCA cycle, fatty acid metabolism, branch chain amino acid catabolism and electron transport chain are downregulated in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mutants, with an increase in proteins associated with glycolysis. (B-K) qPCR analysis of genes representing a subunit from each complex of the electron transport chain (CI: <italic>Ndufb8</italic>, CII: <italic>Sdhb</italic>, CIII: <italic>Uqcrc2</italic>, CIV: <italic>Mtco2</italic> and CV: <italic>Atp5a1</italic>) using 8-week hearts. There was a significant downregulation in Complexes I, II, IV, and V in <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> hearts (<italic>n</italic>=5 hearts for each genotype; B-F) and no corresponding decrease in vitamin-treated hearts (<italic>n</italic>=3 hearts for each genotype; G-K). Data are represented as mean ± SEM. ns, nonsignificant, *p &lt; 0.05, **p &lt; 0.01, ****p &lt; 0.0001 by unpaired t-test. Con, control; cKO, <italic>Slc5a6</italic><sup><italic>cKO</italic></sup>; ConV, vitamin-supplemented control; cKOV, vitamin-supplemented <italic>Slc5a6</italic><sup><italic>cKO</italic></sup>.</p></caption><graphic xlink:href="EMS206407-f007"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Summary of quantifiable ECG parameters at different time points</title><p>ECG traces were averaged for the third minute, and the following parameters were calculated for each mouse: PR interval, P duration, QTc interval, ST height and T amplitude. As some parameters could not be quantified the association between the number of quantifiable and non-quantifiable parameters at each time point for each genotype was calculated. *p&lt;0.05, **p &lt; 0.01, ***p &lt; 0.001 (Fishers Exact test).</p></caption><table frame="box" rules="groups"><thead><tr><th valign="middle" align="left" colspan="2" rowspan="2" style="border-top: 1.5px solid #ffffff;border-bottom: 1.5px solid #000000;border-right: 1.5px solid #000000;border-left: 1.5px solid #ffffff"/><th valign="middle" align="center" colspan="4" style="border-top:solid 1.5px #000000;border-left:solid 1.5px #000000">Normal Diet</th><th valign="middle" align="center" colspan="4" style="border:solid 1.5px #000000">Plus Vitamins</th></tr><tr><th valign="middle" align="center" colspan="2" style="border-top:solid 1.5px #000000;border-left:solid 1.5px #000000">Control</th><th valign="middle" align="center" colspan="2" style="border-top:solid 1.5px #000000;border-left:solid 1.5px #000000"><italic>Slc5a6<sup>cKO</sup></italic></th><th valign="middle" align="center" colspan="2" style="border-top:solid 1.5px #000000;border-left:solid 1.5px #000000">Control</th><th valign="middle" align="center" colspan="2" style="border:solid 1.5px #000000"><italic>Slc5a6<sup>cKO</sup></italic></th></tr><tr><th valign="middle" align="center" style="border-left: 1.5px solid #000000">Week</th><th valign="middle" align="center">Parameter</th><th valign="middle" align="center" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>n</italic></th><th valign="middle" align="center" style="border-top:solid 1.5px #000000;border-left: 1.5px solid #000000">%</th><th valign="middle" align="center" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>n</italic></th><th valign="middle" align="center" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000">%</th><th valign="middle" align="center" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>n</italic></th><th valign="middle" align="center" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000">%</th><th valign="middle" align="center" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>n</italic></th><th valign="middle" align="center" style="border-top: 1.5px solid #000000;border-right: 1.5px solid #000000;border-left: 1.5px solid #000000">%</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">8</td><td valign="middle" align="left" style="border-top:solid 1.5px #000000">PR</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>13</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">92.3</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>17</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">58.8</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>12</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">100</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>10</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-right: 1.5px solid #000000;border-left: 1.5px solid">100</td></tr><tr><td valign="middle" align="left" style="border-top:solid 1.5px #000000">P duration</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000">QTc</td><td valign="middle" align="center" rowspan="3" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">100</td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><bold>35.3 ***</bold></td><td valign="middle" align="center" rowspan="3" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">83.3</td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-right: 1.5px solid #000000;border-left: 1.5px solid">90</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000">ST height</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000">T amplitude</td><td valign="middle" align="center" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><bold>41.2 ***</bold></td><td valign="middle" align="center" style="border-top: 1.5px solid #000000;border-right: 1.5px solid #000000;border-left: 1.5px solid #000000">100</td></tr><tr><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">10</td><td valign="middle" align="left" style="border-top: 1.5px solid #000000">PR</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>10</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">90</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>14</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><bold>42.9 *</bold></td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>12</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">91.7</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>10</italic></td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-right: 1.5px solid #000000;border-left: 1.5px solid">100</td></tr><tr><td valign="middle" align="left" style="border-top:solid 1.5px #000000">P duration</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000">QTc</td><td valign="middle" align="center" rowspan="3" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">100</td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><bold>35.7</bold></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">83.3</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000">ST height</td></tr><tr><td valign="middle" align="center" style="border-top: 1.5px solid #000000">T amplitude</td><td valign="middle" align="center" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><bold>50 *</bold></td><td valign="middle" align="center" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000">91.7</td></tr><tr><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">14</td><td valign="middle" align="left" style="border-top: 1.5px solid #000000">PR</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>10</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">100</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>14</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><bold>21.4 ***</bold></td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>12</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">100</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>10</italic></td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-right: 1.5px solid #000000;border-left: 1.5px solid">80</td></tr><tr><td valign="middle" align="left" style="border-top:solid 1.5px #000000">P duration</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000">QTc</td><td valign="middle" align="center" rowspan="3" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">90</td><td valign="middle" align="center" rowspan="2" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000"><bold>35.7 *</bold></td><td valign="middle" align="center" rowspan="3" style="border-top: 1.5px solid #000000;border-left: 1.5px solid">91.7</td><td valign="middle" align="center" rowspan="3" style="border-top: 1.5px solid #000000;border-right: 1.5px solid #000000;border-left: 1.5px solid">90</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000">ST height</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000">T amplitude</td><td valign="middle" align="center" style="border-top: 1.5px solid #000000;border-left: 1.5px solid #000000">61.5</td></tr><tr><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-bottom: 1.5px solid #000000;border-left: 1.5px solid">20</td><td valign="middle" align="left" style="border-top:solid 1.5px #000000">PR</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-bottom: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>10</italic></td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-bottom: 1.5px solid #000000;border-left: 1.5px solid">100</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-bottom: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>14</italic></td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-bottom: 1.5px solid #000000;border-left: 1.5px solid #000000"><bold>7.1 ***</bold></td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-bottom: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>12</italic></td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-bottom: 1.5px solid #000000;border-left: 1.5px solid">100</td><td valign="middle" align="center" rowspan="5" style="border-top: 1.5px solid #000000;border-bottom: 1.5px solid #000000;border-left: 1.5px solid #000000"><italic>10</italic></td><td valign="middle" align="center" rowspan="5" style="border: 1.5px solid">100</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000">P duration</td></tr><tr><td valign="middle" align="left" style="border-top:solid 1.5px #000000">QTc</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000">ST height</td></tr><tr><td valign="middle" align="left" style="border-top: 1.5px solid #000000;border-bottom: 1.5px solid #000000">T amplitude</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Measurements from mitochondrial reconstructions</title><p>Cardiac mitochondrial MCI and volume measurements from normal diet and vitamin-supplemented control and <italic>Slc5a6</italic><sup><italic>cKO</italic></sup> mice at 8 and 20 weeks. * Indicates the significant differences shown in <xref ref-type="fig" rid="F5">Figure 5</xref> and <xref ref-type="supplementary-material" rid="SD1">Figure S6</xref>.</p></caption><table frame="box" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="3" style="border-top: 1px solid #ffffff;border-bottom: 1px solid #000000;border-left: 1px solid #ffffff"/><th valign="middle" align="center" colspan="2" style="border-top:solid 1px #000000;border-left:solid 1px #000000">8 weeks</th><th valign="middle" align="center" colspan="2" style="border-top:solid 1px #000000;border-left:solid 1px #000000">8 weeks</th><th valign="middle" align="center" rowspan="4" style="border-top: 1px solid #ffffff;border-bottom: 1px solid #ffffff;border-left: 1px solid"/><th valign="middle" align="center" colspan="2" style="border-top:solid 1px #000000;border-left:solid 1px #000000">20 weeks</th><th valign="middle" align="center" colspan="2" style="border:solid 1px #000000">20 weeks</th></tr><tr><th valign="middle" align="center" colspan="2" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Normal Diet</th><th valign="middle" align="center" colspan="2" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Plus Vitamins</th><th valign="middle" align="center" colspan="2" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Normal Diet</th><th valign="middle" align="center" colspan="2" style="border:solid 1px #000000">Plus Vitamins</th></tr></thead><tbody><tr><td valign="middle" align="center" style="border-top:hidden;border-left:hidden"/><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Con</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">cKO</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ConV</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">cKOV</td><th valign="middle" align="center" style="border-top: 1px solid #ffffff;border-bottom: 1px solid #ffffff;border-left: 1px solid"/><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Con</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">cKO</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ConV</td><td valign="middle" align="center" style="border:solid 1px #000000">cKOV</td></tr><tr><td valign="middle" align="center" style="border-left:solid 1px #000000;border-bottom:solid 1px #000000; border-top:solid 1px #000000;"><bold>No. of Mitochondria</bold></td><td valign="middle" align="center" style="border:solid 1px #000000">251</td><td valign="middle" align="center" style="border:solid 1px #000000">264</td><td valign="middle" align="center" style="border:solid 1px #000000">240</td><td valign="middle" align="center" style="border:solid 1px #000000">261</td><th valign="middle" align="center" style="border-top: 1px solid #ffffff;border-bottom: 1px solid #ffffff;border-left: 1px solid"/><td valign="middle" align="center" style="border:solid 1px #000000">468</td><td valign="middle" align="center" style="border:solid 1px #000000">530</td><td valign="middle" align="center" style="border:solid 1px #000000">241</td><td valign="middle" align="center" style="border:solid 1px #000000">240</td></tr><tr><td valign="middle" align="center" style="border-bottom: 1px solid #000000;border-left: 1px solid #ffffff"><bold>MCI</bold></td><td valign="middle" align="center" style="border-bottom: 1px solid #000000"/><td valign="middle" align="center" style="border-bottom: 1px solid #000000"/><td valign="middle" align="center" style="border-bottom: 1px solid #000000"/><td valign="middle" align="center" style="border-bottom: 1px solid #000000"/><td valign="middle" align="center" style="border-top: 1px solid #ffffff;border-bottom: 1px solid #ffffff"/><td valign="middle" align="center" colspan="4" style="border-bottom: 1px solid #000000;border-right: 1px solid #ffffff"/></tr><tr><td valign="middle" align="center" style="border-left:solid 1px #000000"><bold>Minimum</bold></td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.8192</td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.8307</td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.8681</td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.858</td><td valign="middle" align="center" rowspan="8" style="border-left: 1px solid #000000;border-bottom: 1px solid"/><td valign="middle" align="center" style="border-left:solid 1px #000000">0.8111</td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.8035</td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.8169</td><td valign="middle" align="center" style="border-left:solid 1px #000000;border-right:solid 1px #000000">0.797</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>1Q</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.9206</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.9612</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.9984</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.9751</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.071</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.006</td><td valign="middle" align="center" style="border:solid 1px #000000">0.9157</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>Median</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.005</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.029</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.077</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.059</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.081</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.457</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.145</td><td valign="middle" align="center" style="border:solid 1px #000000">1.081</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>3Q</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.177</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.143</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.212</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.139</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.283</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">2.216</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.287</td><td valign="middle" align="center" style="border:solid 1px #000000">1.267</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>Maximum</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">2.24</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">3.555</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">2.02</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.639</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">4.522</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">7.741</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">2.737</td><td valign="middle" align="center" style="border:solid 1px #000000">2.578</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>Range</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.42</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">2.725</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.152</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.7807</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">3.71</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">6.937</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.92</td><td valign="middle" align="center" style="border:solid 1px #000000">1.781</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>Mean</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.067</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.133*</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.129</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.083</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.241</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.848*</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.211</td><td valign="middle" align="center" style="border:solid 1px #000000">1.14*</td></tr><tr><td valign="middle" align="center" style="border:solid 1px #000000"><bold>SD</bold></td><td valign="middle" align="center" style="border:solid 1px #000000">0.212</td><td valign="middle" align="center" style="border:solid 1px #000000">0.3401</td><td valign="middle" align="center" style="border:solid 1px #000000">0.1924</td><td valign="middle" align="center" style="border:solid 1px #000000">0.1337</td><td valign="middle" align="center" style="border:solid 1px #000000">0.4727</td><td valign="middle" align="center" style="border:solid 1px #000000">1.08</td><td valign="middle" align="center" style="border:solid 1px #000000">0.3161</td><td valign="middle" align="center" style="border:solid 1px #000000">0.2901</td></tr><tr><td valign="middle" align="center" style="border-bottom: 1px solid #000000;border-left: 1px solid #ffffff"><bold>Volume</bold></td><td valign="middle" align="center" style="border-bottom: 1px solid #000000"/><td valign="middle" align="center" style="border-bottom: 1px solid #000000"/><td valign="middle" align="center" style="border-bottom: 1px solid #000000"/><td valign="middle" align="center" style="border-bottom: 1px solid #000000"/><td valign="middle" align="center" style="border-top: hidden"/><td valign="middle" align="center" colspan="4" style="border-bottom: 1px solid #000000;border-right: 1px solid #ffffff"/></tr><tr><td valign="middle" align="center" style="border-left:solid 1px #000000"><bold>Minimum</bold></td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.0283</td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.047</td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.0711</td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.0526</td><td valign="middle" align="center" rowspan="8" style="border-left: 1px solid #000000;border-bottom: 1px solid #ffffff"/><td valign="middle" align="center" style="border-left:solid 1px #000000">0.0154</td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.0107</td><td valign="middle" align="center" style="border-left:solid 1px #000000">0.0492</td><td valign="middle" align="center" style="border-left:solid 1px #000000;border-right:solid 1px #000000">0.0327</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>1Q</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.4327</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.3779</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.4342</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.5558</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.289</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.2039</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.3973</td><td valign="middle" align="center" style="border:solid 1px #000000">0.3547</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>Median</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.74</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.6251</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.8492</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.7988</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.4744</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.3562</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.7307</td><td valign="middle" align="center" style="border:solid 1px #000000">0.6477</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>3Q</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.132</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.018</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.255</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.173</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.7295</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.5963</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">1.074</td><td valign="middle" align="center" style="border:solid 1px #000000">1.005</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>Maximum</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">3.855</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">3.67</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">3.889</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">4.139</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">3.861</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">2.581</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">5.65</td><td valign="middle" align="center" style="border:solid 1px #000000">2.657</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>Range</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">3.826</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">3.623</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">3.817</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">4.086</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">3.845</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">2.57</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">5.6</td><td valign="middle" align="center" style="border:solid 1px #000000">2.624</td></tr><tr><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>Mean</bold></td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.835</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.7909*</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.9673</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.9284</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.5892</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.4399*</td><td valign="middle" align="center" style="border-top:solid 1px #000000;border-left:solid 1px #000000">0.8423</td><td valign="middle" align="center" style="border:solid 1px #000000">0.7189</td></tr><tr><td valign="middle" align="center" style="border:solid 1px #000000"><bold>SD</bold></td><td valign="middle" align="center" style="border:solid 1px #000000">0.5573</td><td valign="middle" align="center" style="border:solid 1px #000000">0.5977</td><td valign="middle" align="center" style="border:solid 1px #000000">0.7191</td><td valign="middle" align="center" style="border:solid 1px #000000">0.5457</td><td valign="middle" align="center" style="border:solid 1px #000000">0.4757</td><td valign="middle" align="center" style="border:solid 1px #000000">0.3263</td><td valign="middle" align="center" style="border:solid 1px #000000">0.7073</td><td valign="middle" align="center" style="border:solid 1px #000000">0.4487</td></tr></tbody></table></table-wrap></floats-group></article>